Methods of treating interstitial lung disease and other fibrosis-mediated lung diseases and disorders with deuterated pirfenidone

CN118973575APending Publication Date: 2024-11-15PURETECH LYT 100 INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030884.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-13
Filing Date
2023-03-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing anti-fibrotic drugs such as pirfenidone are poorly tolerated in the treatment of interstitial lung diseases and other fibrosis-mediated lung diseases, resulting in dose-limiting side effects and toxicity, limiting the use and therapeutic effects of the drug. .

Method used

Treatment with deuterium-rich pirfenidone (LYT-100) is used to adjust the dose and administration frequency to achieve drug exposure that is the same as or higher than its systemic exposure, reducing side effects and improving tolerance.

Benefits of technology

Improves the tolerance of patients to anti-fibrotic drugs, allows for higher dose use, extends treatment duration, reduces treatment interruptions and dose reductions, and enhances the effectiveness of treatment and the quality of life of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973575A_ABST
    Figure CN118973575A_ABST
Patent Text Reader

Abstract

Disclosed herein is a method of treating interstitial lung disease and other fibrosis-mediated lung diseases or conditions. The method comprises administering to a subject in need thereof a deuterium-rich pirfenidone LYT-100 in a total daily dose of from about 825 mg to about 2475 mg.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 432,208, filed December 13, 2022, and claims the benefit of U.S. Provisional Application No. 63 / 431,530, filed December 9, 2022, and claims the benefit of U.S. Provisional Application No. 63 / 403,481, filed September 2, 2022, and claims the benefit of U.S. Provisional Application No. 63 / 374,362, filed September 1, 2022, and claims the benefit of U.S. Provisional Application No. 63 / 356,653, filed June 29, 2022, and claims the benefit of U.S. Provisional Application No. 63 / 352,107, filed June 14, 2022, and claims the benefit of U.S. Provisional Application No. 63 / 352,107, filed May 13, 2022 Claiming the benefit of U.S. Provisional Application No. 63 / 341,828, filed on May 12, 2022, and claiming the benefit of U.S. Provisional Application No. 63 / 341,269, filed on May 12, 2022, and claiming the benefit of U.S. Provisional Application No. 63 / 341,279, filed on May 12, 2022, and claiming the benefit of U.S. Provisional Application No. 63 / 341,281, filed on May 12, 2022, and claiming the benefit of U.S. Provisional Application No. 63 / 326,132, filed on March 31, 2022, and claiming the benefit of U.S. Provisional Application No. 63 / 326,129, filed on March 31, 2022, all of which are incorporated herein by reference in their entirety and for all purposes. Background Art

[0003] Current antifibrotic drugs especially have poor drug tolerance problems, including dose-limiting side effects and toxicity associated with gastrointestinal intolerance (e.g., nausea, diarrhea and other GI events), headaches and photosensitivity and other adverse side effects, which significantly limit the current treatment of interstitial lung disease and other fibrosis-mediated lung diseases and conditions. Such dose-limiting side effects and / or toxicity are usually required and therefore managed by one or more of the following treatment options: administering a lower, lower effective dose, regularly reducing the effective dose, regularly or permanently stopping the drug (treatment interruption or suspension) and / or being unable to maintain a patient's continuous treatment program or long-term maintenance dose (e.g., no treatment interruption). For example, pirfenidone (pirfenidone) (currently approved by the FDA in the U.S. for the treatment of idiopathic pulmonary fibrosis (IPF) in only two drugs) has a poor tolerance problem, which significantly limits the use of the drug, thereby resulting in dose reduction, drug conversion and / or antifibrotic therapy interruption or suspension. Studies (see, e.g., Dempsey, 2021) have shown that only 21% of patients who started treatment with pirfenidone were still using the recommended dose of pirfenidone after 2 years. Poor tolerability and its previously mentioned treatment management, including a significant incidence of permanent dose reductions and treatment discontinuations, are associated with reduced clinical efficacy and the chance of losing complete clinical benefit.

[0004] Therefore, there is a need for therapies with superior tolerability profiles compared to antifibrotic drugs currently used to treat interstitial lung disease and other fibrosis-mediated lung diseases and conditions. In particular, there is a need for treatment options that allow administration that can achieve higher drug exposure than current treatment options, which are limited due to dose-limiting side effects and / or toxicity, and that have superior tolerability characteristics compared to current antifibrotic drugs or both, so that continuous (e.g., uninterrupted) treatment can be maintained. Summary of the invention

[0005] In one aspect, a method of treating interstitial lung disease or other fibrosis-mediated lung diseases or conditions is provided, the method comprising administering to a subject in need thereof a total daily dose of about 825 mg to about 2475 mg of a deuterium-enriched pirfenidone having the structure:

[0006]

[0007] wherein the subject's interstitial lung disease or other fibrosis-mediated lung disease or disorder is treated.

[0008] In some embodiments, the total daily dose is 1650 mg.

[0009] In some embodiments, the total daily dose is 2475 mg.

[0010] In some embodiments, the total daily dose is administered in three equal doses.

[0011] In some embodiments, the total daily dose is administered in three equal doses of 825 mg each (825 mg TID).

[0012] In some embodiments, the total daily dose is administered in three equal doses of 550 mg each (550 mg TID).

[0013] In some embodiments, LYT-100 is administered without regard to food.

[0014] In some embodiments, LYT-100 is administered without food.

[0015] In some embodiments, LYT-100 is administered with food.

[0016] In some embodiments, LYT-100 is administered without dose escalation.

[0017] In some embodiments, administering comprises titrating up to the total daily dose from an initial total daily dose that is less than the total daily dose.

[0018] In some embodiments, administration comprises titrating upward from an initial total daily dose that is less than the total daily dose to the total daily dose, and wherein titration comprises administering LYT-100 at 550 mg three times a day for an initial period of time, followed by administering LYT-100 at 825 mg three times a day for a period of time. In some embodiments, titration comprises administering LYT-100 at 275 mg three times a day for an initial period of time, followed by administering LYT-100 at 550 mg three times a day for a period of time, optionally followed by administering LYT-100 at 825 mg three times a day. In some embodiments, the initial period of time is 3 days to 14 days. In some embodiments, the initial period of time is 3 days to 7 days.

[0019] In some embodiments, pulmonary disease or illness of fibrosis mediation are interstitial lung disease (ILD).In some embodiments, ILD is the ILD related to exposure, drug-induced ILD, autoimmune interstitial lung disease, the interstitial lung disease (uILD) that can not be classified, progressive fibrosing interstitial lung disease (pfILD), respiratory bronchiolitis-ILD ​​(RB-ILD), the ILD (CTD-ILD) that connective tissue disease is relevant, rheumatoid arthritis (RA-ILD), systemic sclerosis (SSc-ILD), mixed connective tissue disease-ILD, the ILD that scleroderma is relevant or the ILD relevant to chronic sarcoidosis.In some embodiments, ILD is progressive fibrosing ILD (PF-ILD).

[0020] In some embodiments, the interstitial lung disease or disorder is not idiopathic pulmonary fibrosis (IPF).

[0021] In some embodiments, interstitial lung disease or other fibrosis-mediated lung disease or disorder is alleviated.

[0022] In some embodiments, the progression of interstitial lung disease or other fibrosis-mediated lung disease or disorder is delayed, slowed or arrested.

[0023] In another aspect, a method of treating interstitial lung disease or other fibrosis-mediated lung disease or condition is provided, the method comprising administering to a subject in need thereof a deuterium-enriched pirfenidone having the structure:

[0024]

[0025] wherein the administration is at a dose that achieves in the subject a systemic exposure of LYT-100 that is the same as or about the same as the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg.

[0026] In some embodiments, the dosage of LYT-100 is a total daily dose of 1650 mg.

[0027] In some embodiments, the total daily dose is administered in three equal doses.

[0028] In some embodiments, the total daily dose is administered in three equal doses of 550 mg each (550 mg TID).

[0029] In some embodiments, LYT-100 is administered without regard to food.

[0030] In some embodiments, LYT-100 is administered without food.

[0031] In some embodiments, LYT-100 is administered with food.

[0032] In some embodiments, LYT-100 is administered without dose escalation.

[0033] In some embodiments, pulmonary disease or illness of fibrosis mediation are interstitial lung disease (ILD).In some embodiments, ILD is the ILD related to exposure, drug-induced ILD, autoimmune interstitial lung disease, the interstitial lung disease (uILD) that can not be classified, progressive fibrosing interstitial lung disease (pfILD), respiratory bronchiolitis-ILD ​​(RB-ILD), the ILD (CTD-ILD) that connective tissue disease is relevant, rheumatoid arthritis (RA-ILD), systemic sclerosis (SSc-ILD), mixed connective tissue disease-ILD, the ILD that scleroderma is relevant or the ILD relevant to chronic sarcoidosis.In some embodiments, ILD is progressive fibrosing ILD (PF-ILD).

[0034] In some embodiments, the interstitial lung disease or disorder is not idiopathic pulmonary fibrosis (IPF).In some embodiments, the interstitial lung disease or other fibrosis-mediated lung disease or disorder is alleviated.

[0035] In some embodiments, the progression of interstitial lung disease or other fibrosis-mediated lung disease or disorder is delayed, slowed or arrested.

[0036] In yet another aspect, a method of treating interstitial lung disease or other fibrosis-mediated lung disease or condition is provided, the method comprising administering to a subject in need thereof a deuterium-enriched pirfenidone having the structure:

[0037]

[0038] wherein the administration is at a dose that achieves in the subject a systemic exposure of LYT-100 that is greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg.

[0039] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0040] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is about 1.1x to about 1.9x the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0041] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is about 1.25x to about 1.75x the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0042] In some embodiments, the dose of LYT-100 administered achieves a systemic exposure that is 1.25x to 1.75x the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg.

[0043] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is about 1.4x to 1.6x the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0044] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is 1.4x to 1.5x the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0045] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is about 1.5x the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0046] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is about 85% to about 125% of the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0047] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is 125% to 175% of the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0048] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is 140% to 160% greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0049] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is 140% to 150% greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0050] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is about 150% of the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0051] In some embodiments, the administration is at a dose that achieves in the subject a systemic exposure of LYT-100 that is about 10% to about 90% of the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0052] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is about 25% to about 75% of the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0053] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in a subject that is 25% to 75% greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID). In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in a subject that is 40% to 60% greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0054] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is 40% to 50% greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0055] In some embodiments, the administration is at a dose that achieves a systemic exposure of LYT-100 in the subject that is about 50% greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, optionally wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0056] In some embodiments, the dose of LYT-100 that achieves a systemic exposure of LYT-100 in a subject that is greater than the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg is a total daily dose of 2475 mg.

[0057] In some embodiments, the total daily dose is administered in three equal doses.

[0058] In some embodiments, the total daily dose is administered in three equal doses of 825 mg each (825 mg TID).

[0059] In some embodiments, LYT-100 is administered without regard to food.

[0060] In some embodiments, LYT-100 is administered without food.

[0061] In some embodiments, LYT-100 is administered with food.

[0062] In some embodiments, LYT-100 is administered without dose escalation.

[0063] In some embodiments, administering comprises titrating up to the total daily dose from an initial total daily dose that is less than the total daily dose.

[0064] In some embodiments, administration comprises titrating upward from an initial total daily dose that is less than the total daily dose to the total daily dose, and wherein titration comprises administering LYT-100 at 550 mg three times a day for an initial period of time, followed by administering LYT-100 at 825 mg three times a day for a period of time. In some embodiments, titration comprises administering LYT-100 at 275 mg three times a day for an initial period of time, followed by administering LYT-100 at 550 mg three times a day for a period of time, optionally followed by administering LYT-100 at 825 mg three times a day. In some embodiments, the initial period of time is 3 days to 14 days. In some embodiments, the initial period of time is 3 days to 7 days.

[0065] In some embodiments, fibrosis or collagen-mediated disease or illness are interstitial lung disease (ILD).In some embodiments, ILD is to expose relevant ILD, drug-induced ILD, autoimmune interstitial lung disease, interstitial lung disease (uILD) that can not be classified, progressive fibrosing interstitial lung disease (pfILD), respiratory bronchiolitis-ILD ​​(RB-ILD), the ILD (CTD-ILD) that connective tissue disease is relevant, rheumatoid arthritis (RA-ILD), systemic sclerosis (SSc-ILD), mixed connective tissue disease-ILD, the ILD that scleroderma is relevant or the ILD relevant to chronic sarcoidosis.In some embodiments, ILD is progressive fibrosing ILD (PF-ILD).

[0066] In some embodiments, the fibrotic or collagen-mediated disease or disorder is not idiopathic pulmonary fibrosis (IPF).

[0067] In some embodiments, a fibrosis or collagen-mediated disease or disorder is alleviated.

[0068] In some embodiments, the progression of a fibrosis or collagen-mediated disease or disorder is delayed, slowed or arrested. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] Figure 1 is a graphical illustration of a crossover clinical trial study design according to a non-limiting embodiment of the present disclosure.

[0070] Figure 2 is a graphical illustration of another crossover clinical trial study design according to a non-limiting embodiment of the present disclosure.

[0071] Figure 3The extrapolated steady-state exposure (AUC ) of LYT-100 for 450 mg to 550 mg TID dosing is shown based on PK data from two separate groups (12A and 12B) and the combined data set. 24ss ) and steady-state C max After administration of LYT-100 (1000 mg BID) or pirfenidone (801 mg TID), the steady-state AUC 0-24 Pharmacokinetic parameters were calculated. The data showed that a dose of 550 mg TID LYT-100 had a steady-state exposure (AUC) calculated to be 98.5% of the steady-state exposure (AUC) of pirfenidone administered at 801 mg TID, and a C max 67.4% C max .

[0072] Figure 4 The extrapolated steady-state exposure (AUC) of LYT-100 was shown for 700 mg–1000 mg BID dosing (1400 mg–2000 mg daily dose) and 450 mg–850 mg TID dosing (1350 mg–2550 mg daily dose). 24ss ) and steady-state C max The data show that a dose of 825 mg BID LYT-100 (1650 mg daily dose) has a steady-state exposure (AUC) calculated to be 98.5% of the steady-state exposure (AUC) of pirfenidone administered at 801 mg TID and its steady-state C max In contrast, a dose of 550 mg TID LYT-100 (1650 mg daily dose) had a steady-state exposure (AUC) calculated to be 98.5% of the steady-state exposure (AUC) of pirfenidone administered at 801 mg TID and its steady-state C max 67.4%.

[0073] Figure 5A This is a summary of the pharmacokinetic and tolerability results from a Phase 1 crossover study in healthy adults dosed with 850 mg BID LYT-100.

[0074] Figure 5Bis a table showing the incidence of treatment-emergent adverse events (TEAEs) in a crossover study comparing LYT-100 850 mg BID to pirfenidone 801 mg TID in healthy elderly subjects. The data show that the incidence of gastrointestinal AEs with LYT-100 was 37.1% (LYT-100) vs. 29.7% (pirfenidone); the incidence of nervous system AEs was 45.7% (LYT-100) vs. 35.1% (pirfenidone); and both LYT-100 and pirfenidone increased the incidence of nausea when administered after fasting.

[0075] Figure 6 is a graphic depiction of the side effects encountered in a healthy elderly patient population with LYT-100 550 mg TID and pirfenidone 801 mg TID.

[0076] Fig. 7A is a graphical depiction of time versus exposure for LYT-100 at a dose of 550 mg TID.

[0077] Figure 7B is a graphical depiction of time versus exposure for LYT-100 at a dose of 824 mg TID.

[0078] Figure 7C is a graphical depiction of the time versus exposure of the major metabolites at a dose of 550 mg TID.

[0079] Fig.7D is a graphical depiction of the time versus exposure of the major metabolites at a dose of 824 mg TID.

[0080] Figure 8 is a table showing the pharmacokinetic parameters of LYT-100 and major metabolites at doses of 550 mg TID and 824 mg TID.

[0081] Fig. 9A is a graphical depiction of the time versus exposure of LYT-100 for doses of 550 mg TID and 824 mg TID in the crossover study of Example 1 and two prior dosing studies.

[0082] Fig. 9B is a graphical depiction of the timing versus exposure of the major metabolites for doses of 550 mg TID and 824 mg TID in the crossover study of Example 1 and two prior dosing studies.

[0083] Fig.10 is a graphical illustration of the mean plasma concentrations over time for pirfenidone dosed at 801 mg TID and LYT-100 dosed at 550 mg TID and 824 mg TID.

[0084] Fig.11 is a graphical illustration of the mean plasma concentrations over time of the major metabolites of pirfenidone administered at 801 mg TID and LYT-100 administered at 550 mg TID and 824 mg TID.

[0085] Fig.12 is a graphical depiction of plasma concentrations versus time for pirfenidone 550 mg TID and LYT-100 824 mg TID after day 3 in the crossover study of Example 1.

[0086] Fig.13A is a graphical depiction of subject body weight relative to exposure to LYT-100 for the 550 mg TID and 824 mg TID doses in the crossover study of Example 1 and three prior dosing studies.

[0087] Fig. 13B is a graphical depiction of subject body weight relative to exposure to the major metabolite for the 550 mg TID and 824 mg TID doses in the crossover study of Example 1 and three prior dosing studies.

[0088] Fig.14A is a graphical depiction of subject age relative to exposure to LYT-100 normalized to 550 mg TID in the crossover study of Example 1 and three prior dosing studies.

[0089] Fig. 14B is a graphical depiction of subject age relative to exposure to the major metabolites of LYT-100 normalized to 550 mg TID in the crossover study of Example 1 and three prior dosing studies.

[0090] Fig.15A is a graphical summary of exposure versus dose in the crossover study of Example 1 and previous dosing studies, which demonstrates that bioequivalence of 550 mg TID LYT-100 and 801 mg TID pirfenidone is achieved.

[0091] Fig. 15B is a graphical summary of exposure versus dose in the crossover study of Example 1 and previous dosing studies, which demonstrates that bioequivalence of 550 mg TID LYT-100 and 801 mg TID pirfenidone is achieved.

[0092] Fig. 15C is a graphical summary of exposure versus dose in the crossover study of Example 1 and previous dosing studies, which demonstrates that bioequivalence of 550 mg TID LYT-100 and 801 mg TID pirfenidone is achieved.

[0093] Fig.15Dis a graphical summary of exposure versus dose in the crossover study of Example 1 and pooled data from previous dosing studies demonstrating that bioequivalence of 550 mg TID LYT-100 and 801 mg TID pirfenidone was achieved.

[0094] Fig.16 is a graphical summary of exposure versus dose from the combined data from the crossover study of Example 1 and three prior dosing studies and demonstrates that bioequivalence of 550 mg TID and 687 mg TID LYT-100 to 801 mg TID pirfenidone was achieved.

[0095] Fig.17 is a table showing the predicted bioequivalence of various LYT-100 TID doses using data from the crossover study of Example 1 and three prior dosing studies.

[0096] Fig.18A is a graphical sketch illustrating the predicted plasma concentrations over time for 801 mg TID of pirfenidone, 550 mg TID of LYT-100, and 825 mg TID of LYT-100.

[0097] Fig.18B is a table showing the ratio of predicted plasma concentrations of pirfenidone at 801 mg TID and LYT-100 dosed at 550 mg TID and 825 mg TID.

[0098] Fig.19 is a table showing a summary of the baseline demographic characteristics regarding age and gender of the subjects in the COVID-19 clinical study of Example 3.

[0099] Fig. 20 is a table showing a summary of the baseline demographic characteristics of the subjects in the COVID-19 clinical study of Example 3 with respect to race, ethnicity, and time from COVID diagnosis.

[0100] Fig.21 is a table summarizing the distribution of subjects in the selected population in the COVID-19 clinical study of Example 3.

[0101] Fig. 22 This is a table showing a summary of adverse events that occurred during treatment that were judged to be at least potentially related to LYT-100 in the COVID-19 clinical study of Example 3.

[0102] Fig.23 is a table showing the metabolism of pirfenidone and LYT-100 in the presence of individual CYP isozymes in the assay of Example 4.

[0103] Fig.24is a graphical depiction of the activity results of LYT-100 and pirfenidone in the BioMAP Fibrosis Panel of Example 5.

[0104] Fig.25A is a graphical illustration showing that the TNF-α response to LPS was reduced by pretreatment with pirfenidone and LYT-100.

[0105] Fig.25B is a graphical illustration showing that IL-6 response to LPS is reduced by pretreatment with pirfenidone and LYT-100.

[0106] Fig.26 Depicted are representative photomicrographs of Sirius red-stained liver sections demonstrating that LYT-100 significantly reduced the area of ​​fibrosis.

[0107] Fig. 27 is a graphical illustration showing the percentage of fibrosis area for LYT-100 relative to vehicle and control.

[0108] Fig.28A is a graphic illustration showing that LYT-100 does not induce survival of primary mouse lung fibroblasts (PMFL).

[0109] Fig.28B and Fig.28C is a graphical illustration showing that LYT-100 reduces TGF-β-induced total collagen levels in PMFL in 6-well and 96-well formats, respectively.

[0110] Fig.28D and Fig.28E is a graphical illustration showing that LYT-100 reduces TGF-β-induced soluble fibronectin levels and soluble collagen levels.

[0111] Fig.29A is a graphic illustration showing that LYT-100 does not affect L929 cell survival.

[0112] Fig.29B is a graphical illustration showing that LYT-100 inhibits TGF-induced collagen synthesis.

[0113] Fig.29C is a graphical illustration showing that LYT-100 significantly inhibits TGF-β-induced total collagen levels.

[0114] Fig.29D is a graphical illustration showing that LYT-100 significantly inhibits TGF-β-induced soluble collagen levels.

[0115] Fig.29Eis a graphical illustration showing that LYT-100 significantly reduces soluble fibronectin levels in the absence and presence of TGF-β induction.

[0116] FIG. 30A to FIG. 30D Depicted are the results of once daily administration of LYT-100 to reduce swelling in a mouse lymphedema model.

[0117] Fig.31 is a graphical depiction of the percent body weight change over time in rats in Phase I of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0118] Fig.32A is a graphical depiction of the change in lung weight / body weight percentage over time in rats in Phase I of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0119] Fig.32B is a graphical depiction of the change in lung weight / body weight percentage over time in rats in Phase I of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0120] Fig.33A is a graphical depiction of the changes in body weight over time of rats in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0121] Fig.33B is a graphical depiction of the percent body weight change over time for rats in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0122] Fig.34A is a graphical depiction of the changes in lung weight over time in rats in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0123] Fig.34B is a graphical depiction of the changes in lung weight over time in rats in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0124] Fig.35A is a graphical depiction of the change in lung weight / body weight percentage over time in rats in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0125] Fig.35B is a graphical depiction of the change in lung weight / body weight percentage over time in rats in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0126] Fig.36A is a graphical depiction of the hydroxyproline content in the left lung tissue of rats in stage II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0127] Fig.36Bis a graphical depiction of the hydroxyproline content in the left lung tissue of rats in stage II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0128] Fig.37 : is a table showing the hydroxyproline content in the left lung tissue of different treatment groups in phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0129] Fig.38A is a graphical depiction of the hydroxyproline content in lung tissues in different treatment groups in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0130] Fig.38B is a graphical depiction of the hydroxyproline content in lung tissues in different treatment groups in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0131] Fig.39 is a table showing the hydroxyproline content in lung tissues of different treatment groups in Phase II of the bleomycin-induced pulmonary fibrosis model of Example 11.

[0132] Fig.40A is a graphical depiction of the mean lung fibrosis scores in the different treatment groups in Phase II of the bleomycin-induced lung fibrosis model of Example 11.

[0133] Fig.40B is a graphical depiction of the mean lung fibrosis scores in the different treatment groups in Phase II of the bleomycin-induced lung fibrosis model of Example 11.

[0134] Fig.40C is a graphical depiction of the median lung fibrosis scores in different treatment groups in Phase II of the bleomycin-induced lung fibrosis model of Example 11.

[0135] Fig.40D is a graphical depiction of the median lung fibrosis scores in different treatment groups in Phase II of the bleomycin-induced lung fibrosis model of Example 11.

[0136] Fig.41 is a graphical depiction of the frequency of lung fibrosis scores in different treatment groups in Phase II of the bleomycin-induced lung fibrosis model of Example 11. DETAILED DESCRIPTION

[0137] Disclosed herein is a method for treating interstitial lung disease or other fibrosis-mediated lung diseases or conditions, the method comprising administering LYT-100 to a subject in need thereof. In some embodiments, the method comprises administering a total daily dose of LYT-100 that achieves a systemic exposure comparable to (e.g., the same or approximately the same as) the systemic exposure of a 2403 mg daily dose of pirfenidone (including, for example, 801 mg TID administration). In some embodiments, the method comprises administering a total daily dose of LYT-100 that achieves a systemic exposure greater than the systemic exposure of pirfenidone administered at a daily dose of 2403 mg (e.g., 801 mg TID administration). In some embodiments, the method may result in increased patient compliance, provide a higher LYT-100 exposure than that achieved with a currently approved dose of pirfenidone (801 mg TID), or both, and may ultimately produce more effective therapeutic agents to address the underlying mechanisms of fibrosis or collagen-mediated diseases and conditions.

[0138] Overall, the results disclosed herein indicate that LYT-100 has the potential to be used to treat indications where pirfenidone has shown benefit but where tolerability issues limit its dosage and its potential efficacy. Thus, the disclosed method may be beneficial in treating a range of interstitial lung diseases and other fibrosis-mediated lung diseases and conditions. The features, benefits, and utility of the method will each be further described below.

[0139] definition

[0140] While the terms used herein are believed to be well understood by those of ordinary skill in the art, definitions are set forth herein to facilitate explanation of the presently disclosed subject matter.

[0141] The articles "a" and "an" are used herein to refer to one or to more than one (ie, to at least one) of the grammatical object of the article.

[0142] The term "about" used throughout this specification is used to describe and illustrate small fluctuations. For example, the term "about" can refer to greater than, less than, or equal to ±10%, such as greater than, less than, or equal to ±5%; greater than, less than, or equal to ±2%; greater than, less than, or equal to ±1%; greater than, less than, or equal to ±0.5%; greater than, less than, or equal to ±0.2%; greater than, less than, or equal to ±0.1%; or greater than, less than, or equal to ±0.05%. Whether or not explicitly stated, all numerical values ​​herein are modified by the term "about". Values ​​modified by the term "about" certainly include specific values. For example, "about 5.0" necessarily includes 5.0.

[0143] The term "adverse event" means any event, side effect, or other untoward medical occurrence in humans in conjunction with the use of a medicinal product, whether or not considered to be causally related to such treatment. Thus, an AE can be any unfavorable and unexpected sign (and can include clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. Events that meet the definition of an AE include: exacerbation of a chronic or intermittent pre-existing condition, including an increase in the frequency and / or intensity of the condition; a new condition detected or diagnosed after study drug administration that occurs during the reporting period, even if it may have existed before the start of the study; signs, symptoms, or clinical sequelae of suspected interactions; signs, symptoms, or clinical sequelae of suspected overdose of the study drug or concomitant drug (overdose itself will be reported as an AE / SAE). An AE may be causally related to treatment, may be related, or may not be related. The severity of an AE can be classified as one of the following: Mild (Grade 1): A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. Events generally do not interfere with daily life activities; Moderate (Grade 2): A type of AE that is usually relieved by additional specific treatment interventions. Events interfere with daily life activities and cause discomfort, but do not pose a significant or permanent risk of harm to study participants; Severe (Grade 3): A type of AE that interrupts daily life activities, or significantly affects clinical status, or may require intensive treatment intervention; Life-threatening (Grade 4): A type of AE that puts participants at immediate risk of death; Death (Grade 5): An event that leads to death.

[0144] As used herein, the terms "clinically effective amount", "clinically confirmed effective amount" and the like refer to an effective amount of an API shown by clinical trials, such as US Food and Drug Administration (FDA) clinical trials.

[0145] The term "deuterium" when used to describe a given variable position in a molecule or formula, or the symbol "D" when used to represent a given position in a molecular structure diagram, means that the specified position is enriched with deuterium above the naturally occurring deuterium distribution. In some embodiments, the deuterium enrichment at the specified position is deuterium with not less than about 1%, not less than about 5%, not less than about 10%, not less than about 20%, not less than about 50%, not less than about 70%, not less than about 80%, not less than about 90%, not less than about 98%, or in some embodiments not less than about 99%. In some embodiments, the deuterium enrichment at each specified position is greater than 90%. In some embodiments, the deuterium enrichment at each specified position is greater than 95%. In some embodiments, the deuterium enrichment at each specified position is about 99%.

[0146] The term "deuterium enrichment" refers to the percentage of deuterium incorporated instead of hydrogen at a given position in a molecule. For example, a 1% deuterium enrichment at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the distribution of naturally occurring deuterium is about 0.0156%, the deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. Deuterium enrichment can be determined using conventional analytical methods such as mass spectrometry and nuclear magnetic resonance spectroscopy.

[0147] The term "fibrosis" refers to the deposition of extracellular matrix components, excess fibrous connective tissue, or scarring within an organ or tissue.

[0148] The term "idiopathic pulmonary fibrosis (IPF)" refers to a type of lung disease that results in scarring of the lungs (pulmonary fibrosis), where the origin of the disease state may be unknown.

[0149] Terms such as "treating" or "treatment" or "to treat" or "alleviating" or "to alleviate" refer to therapeutic measures that cure, slow down, improve or alleviate one or more symptoms of a diagnosed pathological condition or disorder, stop its progression and / or improve or alleviate a diagnosed pathological condition or disorder. Therefore, those in need of treatment include those who already have the disorder. In some embodiments, treatment can be administered after one or more symptoms have developed. In other embodiments, treatment can be administered in the absence of symptoms. For example, treatment can be administered to susceptible individuals before the onset of symptoms (e.g., based on the history of symptoms and / or based on genetic or other sensitivity factors). Treatment can also be continued after symptoms subside, for example to prevent or delay their recurrence. In some embodiments, a subject's disease or disorder is successfully "treated" according to the methods provided herein if the patient shows, for example, complete, partial or temporary relief or elimination of symptoms associated with the disease or disorder. "Treatment" may include, but is not limited to, reducing or alleviating one or more symptoms of a disease or condition; delaying, slowing, stopping, improving, alleviating and / or reducing fibrosis; delaying, slowing, stopping, improving or alleviating the progression of a disease or condition; delaying, slowing, stopping, improving or alleviating the onset of a disease or condition; reducing swelling, inflammation, fibrosis and / or pain; and / or improving lung or respiratory function.

[0150] The term "pirfenidone administered at a dose or dosing that achieves the same or approximately the same systemic exposure" as used in comparison to LYT-100 refers to a dose, dosing, or administration when the AUC of pirfenidone in a subject is the same or approximately the same as the AUC achieved by LYT-100 in a subject at a given dosing of LYT-100. In some cases, "pirfenidone administered at a dose or dosing that achieves the same or approximately the same systemic exposure" may refer to administering pirfenidone to a subject at a total daily dose of 2403 mg. In some cases, "pirfenidone administered at a dose or dosing that achieves the same or approximately the same systemic exposure" may refer to administering pirfenidone to a subject at 801 mg TID.

[0151] The term "pharmaceutical composition" refers to a preparation in a form that makes the biological activity of the active ingredient effective, and that does not contain additional components that are unacceptably toxic to the subject to which the composition is administered. The pharmaceutical composition can be in many dosage forms, such as tablets, capsules, liquids, solutions, soft gels, suspensions, emulsions, syrups, elixirs, tinctures, films, powders, hydrogels, ointments, pastes, creams, lotions, gels, mousses, foams, lacquers, sprays, aerosols, inhalers, sprayers, eye drops, patches, suppositories and / or enemas. The pharmaceutical composition typically includes a pharmaceutically acceptable carrier, and may include one or more buffers (e.g., acetate, phosphate or citrate buffers), surfactants (e.g., polysorbates), stabilizers (e.g., human albumin), preservatives (e.g., benzyl alcohol), penetration enhancers, absorption enhancers and / or other conventional solubilizers or dispersants that enhance bioavailability. The choice of dosage form and excipient depends on the active agent to be delivered and the disease or condition to be treated or prevented, and is routine to one of ordinary skill in the art.

[0152] The terms "subject" and "patient" refer to a mammalian subject, including a human subject. In some embodiments, the patient is a human subject.

[0153] The term "LYT-100" refers to a selectively deuterated form of pirfenidone. Specifically, LYT-100 is 5-(methyl-d3)-1-phenylpyridin-2-(1H)-one (CAS No. 1093951-85-9), which may alternatively be referred to as deuteropirfenidone or 2(1H)-pyridinone, 5-(methyl-d3)-1-phenyl. LYT-100 has the following structure:

[0154]

[0155] The "LYT-100" mentioned herein further includes any hydrate, solvate, crystalline polymorph, amorphous form, etc. of 5-(methyl-d3)-1-phenylpyridin-2-(1H)-one. LYT-100 can be prepared by methods known to those skilled in the art and routine modifications thereof and / or the procedures found in Esaki et al., Tetrahedron 2006, 62, 10954-10961, Smith et al., Organic Syntheses 2002, 78, 51-56, U.S. Pat. No. 3,974,281, U.S. Pat. No. 8,680,123, WO 2003 / 014087, WO 2008 / 157786, WO 2009 / 035598, WO 2012 / 122165, or WO 2015 / 112701; the entire contents of each of these documents and the references cited therein and routine modifications thereof are incorporated herein by reference.

[0156] Interstitial lung disease and other fibrosis-mediated lung diseases Treatments for diseases and conditions

[0157] Pirfenidone

[0158] Pirfenidone CAS#53179-13-8, Pirespa, AMR-69, Pirfenidona / Pirfenidonum / Esbriet / Pirfenex, 5-methyl-1-phenyl-1H-pyridin-2-one, 5-methyl-1-phenyl-2-(1H)-pyridinone, 5-methyl-1-phenylpyridin-2(1H)-one, is an orally administered small molecule with anti-fibrotic effects that has been approved in the United States and elsewhere for the treatment of idiopathic pulmonary fibrosis (IPF).

[0159]

[0160] Pirfenidone has established anti-inflammatory and anti-fibrotic properties. Multiple mechanisms may contribute to the unique characteristics of pirfenidone. Pirfenidone attenuates fibroblast proliferation, the production of fibrosis-related proteins and cytokines, and the biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors (such as TGF-β and platelet-derived growth factor or PDGF) (Schaefer et al., Eur Respir Rev. 2011; 20: 85-97; InterMune UK, Ltd. Summary of Product Characteristics, 2011). Specifically, pirfenidone blocks the production and activity of TGF-β, a key growth factor that increases collagen production while reducing its degradation. In addition, administration of pirfenidone reduces the production of other fibrogenic factors induced by TGF-β, such as fibronectin and connective tissue growth factor (Schaefer et al., 2011). Pirfenidone can block bleomycin-induced PDGF production and fibroblast and hepatic stellate cell proliferation in response to PDGF (DiSario et al., J. Hepatol. 2002 November. 37.5.584-591). Pirfenidone inhibits the expression of TNF-α, IL-6, IL-1, and intercellular adhesion molecule 1 (ICAM-1) (Schaefer et al., 2011). In murine macrophage-like cell lines, pirfenidone inhibited TNF-α production or secretion through a mitogen-activated protein kinase and c-jun N-terminal kinase-independent mechanism and increased the levels of the anti-inflammatory cytokine IL-10 (Schaefer et al., 2011).

[0161] In IPF clinical trials, many of the most common adverse reactions were GI (nausea, abdominal pain, diarrhea, dyspepsia, vomiting, and gastroesophageal reflux disease), in addition to fatigue, rash, and photosensitivity reactions. The frequency of these adverse reactions led to 14.6% of patients discontinuing participation in these clinical trials. In a prospective, real-world observational study of 1009 IPF patients starting pirfenidone, 35% of patients experienced adverse reactions and dose adjustments, 28% of patients discontinued, and 11% of patients had dose adjustments and discontinuations. (Cottin, ERJ Open Res, 2018, 4(4)). Therefore, the overall adoption of antifibrotic drugs (including pirfenidone) is low. A study used the US OptumLabs Data Warehouse to identify 10,996 IPF patients with medical and pharmacy requirements between October 1, 2014 and July 31, 2019. The study showed that 73.6% of IPF patients never received an antifibrotic drug (pirfenidone or nintedanib) during the observation period (Dempsey et al. Ann Am Thorac Soc. 2021; 18(7): 1121-1128). In a large post-marketing analysis of 10,996 patients diagnosed with IPF, only 13.2% received pirfenidone during the 5-year follow-up period, the same percentage as those receiving the other marketed antifibrotic drug, nintedanib. (Dempsey, 2021). AEs were documented as barriers to the adoption and continued use of pirfenidone and nintedanib in IPF patients.

[0162] Nintedanib (Ofev; Boehringer Ingelheim) was approved by the FDA in 2014 for the treatment of patients with idiopathic pulmonary fibrosis. Subsequently, it has been approved for use in slowing down the progression of pulmonary fibrosis in patients with systemic sclerosis (scleroderma) and in patients with other rheumatic diseases with progressive pulmonary fibrosis (progressive fibrosing interstitial lung disease). Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases and non-receptor tyrosine kinases. Specifically, Nintedanib inhibits platelet-derived growth factor (PDGF) receptors-α and-β, fibroblast growth factor (FGF) receptors 1-3, vascular endothelial growth factor (VEGF) receptors 1-3 and fms-like tyrosine kinase-3. Among these tyrosine kinase receptors, FGF, PDGF and VEGF are related to the pathogenesis of idiopathic pulmonary fibrosis. Nintedanib competitively binds to the ATP binding pocket of these receptors and blocks intracellular signaling that is critical for the proliferation, migration and transformation of fibroblasts, representing a fundamental mechanism in the pathology of idiopathic pulmonary fibrosis.

[0163] As reported in the nintedanib (Ofev) prescribing information, nintedanib was associated with multiple side effects in the studies leading to FDA approval. The most common adverse reactions (≥5%) with nintedanib therapy included diarrhea (62%), nausea (24%), abdominal pain (15%), vomiting (12%), elevated liver enzymes (14%), decreased appetite (11%), headache (8%), weight loss (10%), and hypertension (5%). Overall, 21% of patients receiving nintedanib and 15% of patients receiving placebo discontinued treatment due to adverse events. The most common adverse reactions leading to discontinuation of nintedanib were diarrhea, nausea, and decreased appetite. In a 2019 retrospective study, nausea, vomiting, or thrombocytopenia were reported to lead to permanent discontinuation of nintedanib, as well as temporary discontinuation due to common adverse reactions (Nakamura et al. Ann Transl Med. 2019 Jun;7(12):262). Nintedanib may have adverse effects on the liver, and blood tests of liver enzymes are recommended when starting medication and periodically during the first 3 months of treatment.

[0164] Due to poor tolerance, the clinical efficacy of pirfenidone when higher than 801mg TID dosage has not been tested, including gastrointestinal side effects, nausea, weight loss and photosensitivity rash (and other AEs). Although some studies have been carried out using higher doses of pirfenidone, well-controlled efficacy studies have not been carried out with pirfenidone dosages higher than 2403mg daily dosages. Therefore, although high doses of pirfenidone-up to 801mg TID pirfenidone-are associated with improved efficacy in IPF (compared with a dosage less than 2403mg per day), the threshold of improved clinical efficacy has not been reached so far, because the dosage higher than 801mg TID is not tested in well-controlled clinical efficacy studies due to poor tolerance. Therefore, it is clearly necessary to improve the AE profile of pirfenidone while maintaining the anti-inflammatory and anti-fibrotic activity of pirfenidone to treat interstitial lung disease or other fibrosis-mediated lung diseases and new therapies for illness.

[0165] LYT-100 Pharmacology

[0166] As disclosed herein, LYT-100 retains the pharmacology of pirfenidone. In particular, LYT-100 has anti-inflammatory and anti-fibrotic properties consistent with pirfenidone. Preclinical data disclosed herein demonstrate the anti-fibrotic and anti-inflammatory activity of LYT-100 (see, e.g., Examples 6-11). For example, in a rat lipopolysaccharide (LPS) model of systemic inflammation, pretreatment with 100 mg / kg and 300 mg / kg of oral doses of LYT-100 inhibited TNFα and IL-6 (Example 6), while in a streptozotocin-induced non-alcoholic steatohepatitis (NASH) mouse model, 60 mg / kg / day doses of LYT-100 significantly reduced the area of ​​liver fibrosis (Example 7).

[0167] LYT-100 also reduces proinflammatory cytokines and inhibits TGF-β and downstream signaling to inhibit fibrosis in primary mouse lung fibroblasts (Example 8). In particular, LYT-100 was found to: (i) reduce TGF-β-induced cell proliferation; (ii) reduce background and TGF-β-induced insoluble (structural) collagen levels; (iii) reduce both background and TGF-β-induced soluble collagen levels; and (iv) reduce background and TGF-β-induced soluble fibronectin levels in primary mouse lung fibroblasts (Example 8).

[0168] Referring to Example 9, LYT-100 (i) inhibits collagen synthesis in the absence or presence of TGF-β induction; (ii) inhibits total collagen levels in the absence or presence of TGF-β induction; (iii) inhibits soluble collagen levels in the absence or presence of TGF-β induction; and (iv) reduces soluble fibronectin levels in the absence and presence of TGF-β induction.

[0169] In addition, LYT-100 and pirfenidone were evaluated using the DiscoverX BioMAP fibrosis panel as described in Example 5. Similar results were observed for both compounds in the three systems, indicating that the anti-fibrotic profile of pirfenidone was retained in LYT-100.

[0170] LYT-100 showed activity in a mouse model of lymphedema (Example 10) and a bleomycin-induced rat model of pulmonary fibrosis (Example 11).

[0171] LYT-100 maintains the pharmacological characteristics of pirfenidone, and due to the effect of deuterium kinetic isotopes on enzyme kinetics, has different pharmacokinetic characteristics relative to pirfenidone. In addition, LYT-100 has unexpectedly high tolerance, including higher GI tolerance. Pirfenidone deuterated to produce LYT-100 slows down its metabolism (Chen et al., Clinical Phar, in Drug Dev. 2021, 11 (2), 220-234), and the altered metabolism may be related to the reduced side effects and improved tolerance observed with LYT-100. Allows higher doses to obtain greater effectiveness without the side effects observed at the same dose of pirfenidone. This discovery also allows for immediate administration without titration, and potentially more effective treatment of patients

[0172] Thus, in one aspect, a method of treating interstitial lung disease or other fibrosis-mediated lung diseases or conditions is provided, the method comprising administering to a subject in need thereof a total daily dose of about 825 mg to about 2550 mg of a deuterium-enriched pirfenidone having the structure:

[0173]

[0174] wherein the subject's interstitial lung disease or other fibrosis-mediated lung disease or disorder is treated.

[0175] In order to implement the methods disclosed herein (i.e., dose range), a number of dose range PK studies of LYT-100 were conducted (e.g., several dose range MAD studies in the range of 1000 mg to 4000 mg of total daily dose of LYT-100). The PK modeling data incorporates the results of various MAD PK studies to reduce the variability inherent in multiple studies with small sample sizes. The results of the combined data from these various dose ranging studies are shown in Table 18 below, and indicate that: 1) a dose of 550 mg TID LYT-100 had a systemic exposure (AUC) of about 90%-98% (average about 95%) of the AUC achieved with pirfenidone (2403 mg dose, 801 mg TID) and a Cmax of about 73%-80% (average about 77%) of the Cmax achieved with pirfenidone (2403 mg dose, 801 mg TID); and 2) a dose of 825 mg TID had a systemic exposure (AUC) of about 139%-148% (average about 143%) of the AUC achieved with pirfenidone (2403 mg dose, 801 mg TID) and a Cmax of about 109%-121% (average about 115%) of the Cmax achieved with pirfenidone (2403 mg dose, 801 mg TID). Of note, the clinical efficacy of pirfenidone at doses higher than 801 mg TID has not been previously tested due to poor tolerability.

[0176] Table 1 summarizes the pharmacokinetic results of the crossover study of LYT-100 550 mg TID and pirfenidone 801 mg TID. The results are expressed as mean (SD) and show that at the 550 mg TID dose, the AUC of LYT-100 was similar to that of pirfenidone administered at a dose of 801 mg TID, while C max Lower. AUC of LYT-100 and pirfenidone 801 mg TID 0-24 The bioequivalence criteria were met (geometric mean ratio = 0.875; 90% confidence interval = 0.842 to 0.910), while C max Compared with pirfenidone 801 mg TID, 5-carboxypirfenidone, the major metabolite of pirfenidone and LYT-100, showed a lower C after LYT-100 was administered at 550 mg TID. max and AUC 0-24 In the case of LYT-100, the parent and 5-carboxypyrfenidone decreased C maxSimilar levels of total exposure (AUC) are expected to provide efficacy in interstitial lung disease and other fibrosis-mediated lung diseases and conditions, likely due to reduced gastric side effects of pirfenidone. Similar results were also observed on day 4 or day 14 after administration of a single 550 mg dose of LYT-100 or 801 mg pirfenidone in the fasting state (Table 2). max Increase to a smaller extent.

[0177] Table 1: Pharmacokinetics of LYT-100, pirfenidone, and 5-carboxypirfenidone after 3 days of administration in the fed state Learning Parameters

[0178]

[0179] Table 2: Results of 3-day dosing in the fed state followed by a single dose in the fasted state on days 4 / 14 Pharmacokinetic parameters of LYT-100, pirfenidone, and 5-carboxy-pirfenidone

[0180]

[0181] In addition, further PK studies are conducted to determine the dosing frequency and dose amount associated with improved tolerability (compared to currently approved IPF treatments, such as pirfenidone 801 mg TID). The dose that minimizes AEs and has a similar total exposure level (AUC) to pirfenidone 801 mg TID is LYT-100 550 mg TID.

[0182] As shown in Table 3, the PK and AE data of LYT-100 550 mg TID and pirfenidone 801 mg TID in the fed and fasted states were compared (LYT-100-2021-103 Part 2). At 550 mg TID (e.g., a drug exposure level similar to the approved 801 TID pirfenidone), lower AEs were observed for LYT-100 in both the fed and fasted states compared to pirfenidone. Specifically, administration of a daily dose of 1650 mg LYT-100 showed that LYT-100 550 mg TID was associated with improved tolerability compared to pirfenidone, including a 50% reduction in gastrointestinal-related AEs and a 45% reduction in CNS-related AEs (see the results of LYT-100-2021-103 Part 2 shown in Example 1 and Table 3).

[0183] Although the AEs observed with 550 mg TID LYT-100 in the fasted state were higher than those observed in the fed state, the AEs with 550 mg TID LYT-100 in the fasted state were still much lower than the AEs observed with 801 mg TID pirfenidone in the fasted state. These results demonstrate that LYT-100 administered at 550 TID has improved tolerability (fewer AEs) at the same / similar drug exposure level of 801 TID pirfenidone, and if necessary, administration in the fasted state can be selected, such as with individual meal times. These data provide the rationale for selecting a 550 mg TID dose of LYT-100 in the treatment of interstitial lung disease and other fibrosis-mediated lung diseases and conditions. When the AE rate is ranked from lowest to highest, for each of these conditions, the Cmax values ​​of the parent compound are similarly ranked from lowest to highest: lowest AE rate and Cmax to highest AE and Cmax = LYT-100 550 mg (fed) to LYT-100 550 mg (fasted) to pirfenidone 801 mg (fed) to pirfenidone 801 mg (fasted) - Table 3 (LYT-100-2021-103 Part 2). The levels of the 5-carboxyl metabolite were also ranked from lowest to highest in the above order (Table 3) (LYT-100-2021-103 Part 2).

[0184]

[0185] Table 4 summarizes the pharmacokinetic results and shows that at the 550 mg TID dose, the PK parameters of LYT-100 and the metabolite 5-carboxypyrfenidone were similar to those seen in part 2 of the study at the 550 mg TID dose of LYT-100. At the higher dose of 824 mg TID, AUC 0-24 and C max All were higher than pirfenidone; however, the corresponding parameters for the metabolite 5-carboxy pirfenidone were similar / slightly lower. Adverse event data (Table 6) show that the frequency of the most common adverse events was very low even at the 824 mg TID dose. The higher exposure combined with the low frequency of adverse events provides the rationale for using the 825 mg TID dose of LYT-100 in the treatment of interstitial lung disease and other fibrosis-mediated lung diseases and conditions.

[0186] Table 4: Pharmacokinetics of LYT-100, pirfenidone, and 5-carboxypirfenidone after 3 days of administration in the fed state Learning Parameters

[0187]

[0188] The dose of LYT-100 was optimized to achieve a systemic exposure (AUC) similar to that of pirfenidone 801 mg TID. The dose of LYT-100 was also optimized to achieve a Cmax similar to that of pirfenidone 801 mg TID while maximizing exposure (AUC). The Cmax and AUC values ​​obtained using the combined LYT-100 PK data compared to 801 mg TID pirfenidone were confirmed in subsequent individual studies of 550 mg TID LYT-100 and 824 mg TID LYT-100, thus confirming our confidence in the modeling data and the use of 550 mg TID and 825 mg TID LYT-100 doses.

[0189] The dose of LYT-100 was optimized to achieve a Cmax similar to pirfenidone 801 mg TID while maximizing drug exposure (AUC). Study LYT-100-2021-103 Part 3 was a randomized, double-blind, parallel-group, placebo-controlled study in healthy elderly subjects to evaluate the safety and tolerability of high-dose LYT-100 titrated under fed conditions compared to placebo. Based on the observation that lower TID doses of LYT-100 had improved tolerability (but comparable total exposure) compared to pirfenidone in Part 2 (550 TID LYT-100), the decision was made to test the safety and tolerability of higher TID doses of LYT-100 to achieve a higher overall predicted AUC or total exposure than the approved pirfenidone dose (801 mg TID). Subjects aged 60 to 80 years were randomized to receive LYT-100 or placebo. Subjects were dosed up to 550 mg LYT-100 TID for 3 days (to steady state [Day 1 to Day 3]) compared to placebo administered TID for 3 days to steady state. Subjects were dosed 824 mg LYT-100 TID for 3 days on Days 4 to 6 compared to placebo TID for 3 days to steady state. A summary of the dosing regimens is provided in the Examples section below (Example 2).

[0190] Table 5 summarizes the pharmacokinetic results and shows that at the 550 mg TID dose, the PK parameters of LYT-100 and the metabolite 5-carboxypyrfenidone were similar to those seen in part 2 of the study at the 550 mg TID dose of LYT-100. At the higher dose of 824 mg TID, AUC 0-24 and C maxHigher than those seen with pirfenidone 801 mg TID; however, the corresponding parameters for the metabolite 5-carboxy pirfenidone were similar or slightly lower. Adverse event data (Table 6) show that the frequency of the most common adverse events is very low even at the 824 mg TID dose. Higher exposure combined with low frequency of adverse events provides the rationale for using LYT-100 at a dose of 825 mg TID in the treatment of interstitial lung disease and other fibrosis-mediated lung diseases and conditions.

[0191] Table 5: Pharmacokinetics of LYT-100, pirfenidone, and 5-carboxypirfenidone after 3 days of administration in the fed state Learning Parameters

[0192]

[0193]

[0194] Compared to historical pirfenidone PK values, LYT-100 824 mg TID achieved approximately 25% higher AUC and moderately higher Cmax. Surprisingly, as shown in Table 6, this high dose of LYT-100 (825 mg TID) was well tolerated. Prior to completion of the tolerability studies shown in Table 6, it was not known that such a high dose - 825 mg TID LYT-100, which is equivalent to approximately 120-150% exposure of 801 TID pirfenidone - could be sufficiently tolerated to be included in clinical efficacy studies.

[0195] Table 6. Pharmacokinetic parameters and adverse events of LYT-100 and 5-carboxypyrfenidone metabolites

[0196]

[0197]

[0198] Table 7 summarizes the pharmacokinetic results of the 550 mg TID dose and 825 mg TID dose, as well as the observed adverse events and frequencies, and further provides comparative data for pirfenidone in related studies.

[0199]

[0200] The 550 mg TID and 825 mg TID doses of LYT-100 were optimized for key PK parameters and demonstrated improved tolerability compared to the 2304 mg daily dose (801 mg TID) of pirfenidone, surprisingly even at higher systemic drug exposures. This improved tolerability of LYT-100 relative to pirfenidone was unexpected and may significantly improve compliance with continued high-efficiency dosing (e.g., by reducing the frequency of dose reductions, treatment interruptions, and / or temporary or permanent discontinuations experienced with pirfenidone).

[0201] In general, as described in Examples 1 and 2 of the present disclosure, in Parts 1 and 2 of the clinical studies, LYT-100 850 mg BID closely matched the AUC of pirfenidone 801 mg TID and had a slightly higher Cmax; and the 550 mg TID LYT-100 dose matched the AUC (within BE) and had a lower Cmax compared to pirfenidone 801 mg TID. Continuing with reference to the examples, in the first study, on Day 3, the Cmax of LYT-100 550 mg TID administered in the fed state was 1.14 ± 0.03 % (P < 0.05). max 24% lower than pirfenidone 801 mg TID with food and with similar AUC; on day 4, both pirfenidone and 550 mg TID LYT-100 administered in the fasted state resulted in higher drug exposure, with pirfenidone’s C max On day 3, in the fed state, the metabolite C max 46% lower than pirfenidone; and the trend of AE rate was similar to that of parent and metabolite C max The AE rates were consistent (GI 28.3%, 10.6%, 11.1%, 6.5% for pirfenidone fasted, pirfenidone fed, LYT-100 fasted, and LYT-100 fed, respectively; CNS 21.7%, 14.9%, 8.9%, 8.7%). Continuing with reference to the example, in the second study, on Day 3, LYT-100 dosed at 824 mg TID had a 57% higher CNS than LYT-100 dosed at 550 mg. max and 43% higher AUC 0-24 AEs were low and comparable between LYT-100 824 mg TID and placebo (GI 0%, CNS 0%, 16.7% infection (COVID-19) for both groups).

[0202] With further reference to the Examples, the results of Part 3 of the study were unexpected given the predictions based on Parts 1 and 2 of the study. Specifically, 1) LYT-100 550 mg TID had a much lower AUC but similar Cmax compared with Part 2; 2) LYT-100 824 mg TID had a lower AUC than predicted; Cmax was 17% higher than that of pirfenidone; 3) Although higher variability was observed in the PK parameters of LYT-100 in Part 3, the metabolite / parent ratio of LYT-100 was consistently lower compared with pirfenidone (i.e., 5-carboxyl metabolite exposure was lower when the same dose of LYT-100 and pirfenidone were compared); 4) GI AEs and nausea were much lower with LYT-100 (550 mg TID) compared with pirfenidone 801 mg TID; 5) Administration in the fed state reduced GI-related AEs, especially pirfenidone, but LYT-100 had less effect on AEs; 6) GI AEs occurred early in treatment; and 7) LYT-100 at 550 mg TID was significantly lower than that of pirfenidone. Better tolerability at the TID dose allows for better subject compliance with the full dose, which may lead to better clinical outcomes in various interstitial lung diseases and other fibrosis-mediated lung diseases and conditions.

[0203] In the disclosed method, the dosage and frequency of administration vary based on the disease or disorder and its severity as well as the desired pharmacokinetic parameters and tolerability characteristics. In particular, the improved tolerability of LYT-100 (e.g., fewer adverse side effects) can allow administration at therapeutic (effective) levels, for example, including administration at currently approved therapeutic doses of pirfenidone, with less or no treatment interruptions, less or no treatment suspensions, and less or no dose reduction in the treatment of interstitial lung disease and other fibrosis-mediated lung diseases or disorders. This greater tolerability of deuterium-enriched pirfenidone LYT-100 allows for sustained or long-term treatment at therapeutic doses, thereby effectively treating patients with various interstitial lung diseases and other fibrosis-mediated lung diseases and disorders. Improved tolerability also provides the potential for administration without titration or with a reduced titration duration, so as to more quickly and effectively treat patients with various interstitial lung diseases and other fibrosis-mediated lung diseases and disorders. The improved tolerability also provides the potential for higher doses (systemic exposure) to achieve greater effectiveness without the side effects observed at equivalent doses (systemic exposure) of pirfenidone.

[0204] As described above, the method generally comprises administering LYT-100 at a total daily dose of about 825 mg to about 2550 mg of LYT-100. In some embodiments, LYT-100 is administered at a daily dose that achieves the same or approximately the same systemic exposure as pirfenidone administered at a dose of 2403 mg / day. In some embodiments, the method comprises administering a total daily dose of LYT-100 that achieves a systemic exposure greater than the systemic exposure of pirfenidone administered at a daily dose of 2403 mg (e.g., 801 mg TID).

[0205] In some embodiments, the total daily dose is from about 825 mg to about 1650 mg, such as about 825 mg, about 1100 mg, about 1375 mg, or about 1650 mg. In some embodiments, the total daily dose is 825 mg.

[0206] In some embodiments, the total daily dose is about 1650 mg to about 2550 mg of LYT-100, such as about 1650 mg, about 1700 mg, about 1750 mg, about 1800 mg, about 1850 mg, about 1900 mg, about 1950 mg, about 2000 mg, about 2050 mg, about 2100 mg, about 2150 mg, about 2200 mg, about 2250 mg, about 2300 mg, about 2350 mg, about 2400 mg, about 2450 mg, about 2475 mg, about 2500 mg, or about 2550 mg. In some embodiments, the total daily dose is about 1650 mg to about 2475 mg. In some embodiments, the total daily dose is 1650 mg. In some embodiments, the total daily dose is 2475 mg.

[0207] In some embodiments, the total daily dose is administered in three equal doses. In some embodiments, LYT-100 is administered in three equal doses (550 mg TID), 550 mg each time. In some embodiments, LYT-100 is administered in three equal doses (825 mg TID), 825 mg each time. In some embodiments, LYT-100 is administered in three equal doses (275 mg TID), 275 mg each time.

[0208] In some embodiments, LYT-100 is administered without regard to food. In some embodiments, LYT-100 is administered without food. In some embodiments, LYT-100 is administered with food.

[0209] In some embodiments, LYT-100 is administered orally without food in three daily doses of 550 mg each. In some embodiments, LYT-100 is administered orally with food in three daily doses of 550 mg each.

[0210] In some embodiments, LYT-100 is administered orally without food in three daily doses of 825 mg each. In some embodiments, LYT-100 is administered orally with food in three daily doses of 825 mg each.

[0211] In some embodiments, LYT-100 is administered orally without food in three daily doses of 275 mg each. In some embodiments, LYT-100 is administered orally with food in three daily doses of 275 mg each.

[0212] In some embodiments, LYT-100 is administered without dose escalation. In some embodiments, LYT-100 is administered in three equal doses of 550 mg each without dose escalation. In some embodiments, LYT-100 is administered in three equal doses of 825 mg each without dose escalation.

[0213] In some embodiments, LYT-100 is administered in dose escalation. In some embodiments, LYT-100 is administered at doses of 550 mg three times a day for three days, followed by administration of LYT-100 at a dose of 825 mg TID. The crossover study described in Reference Example 2, initial data on the occurrence of adverse events in healthy elderly subjects taking 550 mg TID (1650 mg / day), followed by 824 TID (2472 mg / day) doses, indicates that with this dose titration regimen, adverse events (particularly gastrointestinal (GI) disorders and nervous system disorders) do not increase and may be reduced or even eliminated.

[0214] In some embodiments, administration comprises titrating upward from an initial total daily dose that is less than the total daily dose to the total daily dose, and wherein titration comprises administering LYT-100 at 550 mg three times a day for an initial period of time, followed by administering LYT-100 at 825 mg three times a day for a period of time. In some embodiments, titration comprises administering LYT-100 at 275 mg three times a day for an initial period of time, followed by administering LYT-100 at 550 mg three times a day for a period of time, optionally followed by administering LYT-100 at 825 mg three times a day. In some embodiments, the initial period of time is 3 days to 14 days. In some embodiments, the initial period of time is 3 days to 7 days.

[0215] In contrast, as reported in the regulatory summary leading to the approval of pirfenidone (Esbriet / pirfenidone), increasing daily doses of pirfenidone (801 mg / day, 1602 mg / day, 2403 mg / day, 3204 mg / day, and 4005 mg / day, given in three equal doses) were tested in a panel of healthy elderly subjects (PIPF-005). The number of reported AEs (headache, dyspepsia, nausea, back pain) increased with increasing total daily dose. Higher C at higher doses ma The x value increases the chance of experiencing a gastrointestinal (GI) AE, and it is noted that this is consistent with previous studies of pirfenidone. As reported in study PIPF-005, for a three-times-daily dose of 801 mg (2403 mg / day), C max was 11.85 μg / mL, which falls within the C values ​​reported for 550 mg TID and 824 mg TID in Example 2. max between values.

[0216] In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 825 mg for a first period of time and at a second total daily maintenance dose of 1650 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 1650 mg for a first period of time and at a second total daily maintenance dose of 2475 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 825 mg for a first period of time, at a second total daily dose of 1650 mg for a second period of time, and then at a total maintenance dose of 2475 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 825 mg for a first period of time of about 7 days and at a second total daily maintenance dose of 1650 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 1650 mg for a first period of time of about 7 days and at a second total daily maintenance dose of 2475 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 825 mg for a first period of about 7 days, at a second total daily dose of 1650 mg for a second period of about 7 days, and then at a total maintenance dose of 2475 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 825 mg for a first period of about 14 days and at a second total daily maintenance dose of 1650 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 1650 mg for a first period of about 14 days and at a second total daily maintenance dose of 2475 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 825 mg for a first period of about 14 days, at a second total daily dose of 1650 mg for a second period of about 14 days, and then at a total maintenance dose of 2475 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 825 mg for a first period of about 7 days to 14 days and at a second total daily maintenance dose of 1650 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 1650 mg for a first period of 7 days to 14 days and at a second total daily maintenance dose of 2475 mg. In some embodiments, the method comprises administering LYT-100 at a first total daily dose of 825 mg for a first period of 7 days to 14 days, at a second total daily dose of 1650 mg for a second period of 7 days to 14 days, and then at a total maintenance dose of 2475 mg.

[0217] In some embodiments, the method comprises administering LYT-100 at a dose of 275 mg three times a day for a first period of time and at a second maintenance dose of 550 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 550 mg three times a day for a first period of time and at a second maintenance dose of 825 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 275 mg three times a day for a first period of time, administering at a dose of 550 mg three times a day for a second period of time, and then administering at a maintenance dose of 825 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 275 mg three times a day for a first period of time of about 7 days and at a second maintenance dose of 550 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 550 mg three times a day for a first period of time of about 7 days and at a second maintenance dose of 825 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 275 mg three times a day for a first period of about 7 days, administering at a dose of 550 mg three times a day for a second period of about 7 days, and then administering at a maintenance dose of 825 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 275 mg three times a day for a first period of about 14 days and administering at a second maintenance dose of 550 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 550 mg three times a day for a first period of about 14 days and administering at a second maintenance dose of 825 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 275 mg three times a day for a first period of about 14 days, administering at a dose of 550 mg three times a day for a second period of about 14 days, and then administering at a maintenance dose of 825 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 275 mg three times a day for a first period of 7-14 days and at a second maintenance dose of 550 mg three times a day. In some embodiments, the method comprises administering LYT-100 at a dose of 550 mg three times a day for a first period of 7-14 days and at a second maintenance dose of 825 mg three times a day.In some embodiments, the method comprises administering LYT-100 at a dose of 275 mg three times per day for a first period of 7-14 days, at a dose of 550 mg three times per day for a second period of 7-14 days, and then at a maintenance dose of 825 mg three times per day.

[0218] In any of the above embodiments, LYT-100 is administered orally without food. In any of the above embodiments, LYT-100 is administered orally with food. In any of the above embodiments, LYT-100 is administered orally without regard to food. In any of the above embodiments, the total daily dose (e.g., 825 mg, 1650 mg, or 2475 mg) can be adjusted to a lower daily dose, for example, as described elsewhere in this specification.

[0219] In some embodiments, LYT-100 administered three times a day results in increased tolerability at a total daily dose of 1650-2475 compared to pirfenidone administered TID at 801 mg. In some embodiments, the increased tolerability is due to a reduction in one or more adverse events or side effects. In some embodiments, one or more adverse events are neurological side effects. In some embodiments, one or more adverse events are gastrointestinal events. In some embodiments, LYT-100 is administered orally in three daily doses of 550 mg each time.

[0220] In some embodiments, LYT-100 administered three times daily at a total daily dose of 1650-2475 mg results in a lower steady-state C compared to pirfenidone administered at 801 mg TID. max In some embodiments, LYT-100 is administered orally in three daily doses of 550 mg each.

[0221] In some embodiments, LYT-100 administered in three doses per day at a total daily dose of 1650-2475 results in a steady-state exposure (AUC) of LYT-100 that is the same or approximately the same as the steady-state exposure (AUC) of pirfenidone achieved when pirfenidone is administered TID at 801 mg. In some embodiments, LYT-100 administered in three doses per day at a total daily dose of 1650-2475 results in a steady-state exposure (AUC) of LYT-100 that is bioequivalent to the steady-state exposure (AUC) of pirfenidone when pirfenidone is administered TID at 801 mg. In some embodiments, LYT-100 is administered orally in three daily doses of 550 mg each time.

[0222] In some embodiments, LYT-100 administered three times daily at a total daily dose of 1650-2475 mg results in a steady-state exposure (AUC) of LYT-100 that is the same or about the same as that achieved with pirfenidone when pirfenidone is administered at 801 mg TID, and results in a steady-state C of LYT-100 that is max In some embodiments, the steady-state exposure of LYT-100 is about 90% of the AUC of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, and wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID). In some embodiments, the steady-state C of LYT-100 is about 90% of the AUC of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg. max is the C of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg max About 75%-80% of the total daily dose of pirfenidone, and wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID). In some embodiments, at this dosing, LYT-100 has increased or improved tolerability due to one or more adverse events or side effects compared to pirfenidone administered at 801 mg TID. In some embodiments, LYT-100 is administered orally in three daily doses of 550 mg each.

[0223] In some embodiments, LYT-100 administered three times a day at a total daily dose of 1650-2475 mg results in the same or approximately the same steady-state exposure (AUC) compared to pirfenidone administered at 801 mg TID, and increased or improved tolerability compared to pirfenidone administered at 801 mg TID. In some embodiments, the increased or improved tolerability is due to a reduction in one or more adverse events or side effects. In some embodiments, LYT-100 is administered orally in three daily doses of 550 mg each time.

[0224] In some embodiments, LYT-100 administered three times daily at a total daily dose of 1650-2475 results in higher steady-state exposure (AUC) compared to pirfenidone administered TID at 801 mg. In some embodiments, LYT-100 is administered orally in three daily doses of 825 mg each.

[0225] In some embodiments, LYT-100 administered three times daily at a total daily dose of 1650-2475 results in the same or approximately the same steady-state Cmax as pirfenidone administered TID at 801 mg. In some embodiments, LYT-100 is administered orally in three daily doses of 825 mg each.

[0226] In some embodiments, LYT-100 administered three times daily at a total daily dose of 1650-2475 results in a higher steady-state exposure (AUC) compared to pirfenidone administered at 801 mg TID, and the same or about the same steady-state Cmax compared to pirfenidone administered at 801 mg TID. In some embodiments, LYT-100 is administered orally in three daily doses of 825 mg each.

[0227] In some embodiments, LYT-100 administered three times a day at a total daily dose of 1650-2475 results in a higher steady-state exposure (AUC) compared to pirfenidone administered at 801 mg TID, and has the same or approximately the same tolerability (e.g., no significant difference in the incidence of adverse events) compared to pirfenidone administered at 801 mg TID. In some embodiments, LYT-100 administered three times a day at a total daily dose of 1650-2475 results in a higher steady-state exposure (AUC) compared to pirfenidone administered at 801 mg TID, and has increased or improved tolerability due to a reduction in one or more adverse events or side effects. In some embodiments, LYT-100 is administered orally in three daily doses of 825 mg each time.

[0228] In some embodiments, LYT-100 administered three times a day at a total daily dose of 1650-2475 results in the same or approximately the same steady-state Cmax as pirfenidone administered at 801 mg TID, and has the same or approximately the same tolerability (e.g., no significant difference in the incidence of adverse events) as pirfenidone administered at 801 mg TID. In some embodiments, LYT-100 administered three times a day at a total daily dose of 1650-2475 results in the same or approximately the same steady-state Cmax as pirfenidone administered at 801 mg TID, and has increased or improved tolerability due to a reduction in one or more adverse events or side effects. In some embodiments, LYT-100 is administered orally in three daily doses of 825 mg each time.

[0229] In some embodiments, LYT-100 is administered at a dose that achieves a systemic exposure of LYT-100 in a subject that is about 85%-125% of the systemic exposure of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg, and wherein the total daily dose of pirfenidone is administered in three doses of 801 mg each (801 mg TID).

[0230] In some embodiments, the dose of LYT-100 that achieves a systemic exposure of LYT-100 in a subject that is about 85%-125% of the systemic exposure of pirfenidone is 825 mg TID.

[0231] In some embodiments, the dose of LYT-100 that achieves a systemic exposure of LYT-100 in a subject that is about 85%-125% of the systemic exposure of pirfenidone is about 10% to about 20% of the systemic exposure of pirfenidone. max , which is the C of pirfenidone achieved when pirfenidone is administered at a total daily dose of 2403 mg. max About 115%-125% of, and wherein the total daily dose of pirfenidone is administered in three doses, 801 mg each time (801 mg TID). In some embodiments, under this administration, LYT-100 has the same or approximately the same tolerability (e.g., no significant difference in the incidence of adverse events) compared to pirfenidone administered at 801 mg TID. In some embodiments, under this administration, LYT-100 has increased or improved tolerability due to one or more adverse events or side effects compared to pirfenidone administered at 801 mg TID. In some embodiments, LYT-100 is orally administered in three daily doses, 825 mg each time.

[0232] As described above, in some embodiments, administration of LYT-100 according to the disclosed methods results in increased or improved tolerability due to a reduction in one or more adverse events or side effects in a subject compared to pirfenidone administered at a dose or dosing that achieves the same or approximately the same systemic exposure.

[0233] In any one of these embodiments where one or more side effects are reduced, incidence, severity or both can be reduced. In some embodiments, compared with the pirfenidone administered with a dosage or administration to achieve the same or roughly the same systemic exposure, the incidence of side effects in individual patients or patient populations (i.e., the frequency of side effects) is reduced by at least 30%. For example, in some embodiments, compared with the pirfenidone administered with a dosage or administration to achieve the same or roughly the same systemic exposure, the incidence of side effects is reduced by at least 35%, at least 40% or at least about 50%. In some embodiments, compared with the pirfenidone administered with a total daily dose of 2403 mg (including, for example, 801 mg TID), the incidence of side effects is reduced by at least 30%.

[0234] In some embodiments, the incidence of side effects is reduced when the subject is administered in the fed state, compared to a dose or administration of pirfenidone that achieves the same or approximately the same systemic exposure in the fed state. In some embodiments, the incidence of side effects is reduced when the subject is administered in the fasted state, compared to a dose or administration of pirfenidone that achieves the same or approximately the same systemic exposure in the fasted state.

[0235] In some embodiments, one or more side effects are gastrointestinal side effects. In some embodiments, one or more side effects are nervous system side effects. In some embodiments, one or more side effects are a combination of gastrointestinal side effects and nervous system side effects. Examples of gastrointestinal side effects include nausea, vomiting, and abdominal pain or bloating.

[0236] In some embodiments, the nervous system and / or gastrointestinal side effects in a subject are reduced by administering LYT-100 at a total daily dose of 1650 mg, optionally wherein LYT-100 is administered TID. In some embodiments, the nervous system and / or gastrointestinal side effects in a subject are reduced by administering LYT-100 at a total daily dose of 2475 mg, optionally wherein LYT-100 is administered TID.

[0237] Interstitial lung disease and other fibrosis-mediated lung diseases and conditions The disclosed methods generally treat interstitial lung disease and other fibrosis-mediated lung diseases and conditions. Thus, the methods can treat a variety of diseases and conditions of a fibrotic and / or inflammatory nature. In some embodiments, interstitial lung disease or other fibrosis-mediated lung disease or condition or its symptoms are alleviated. In some embodiments, the onset of interstitial lung disease or other fibrosis-mediated lung disease or condition is delayed, slowed or contained. In some embodiments, the progression of interstitial lung disease or other fibrosis-mediated lung disease or condition is delayed, slowed or contained.

[0238] Interstitial lung disease and other fibrosis-mediated lung disorders

[0239] In some embodiments, the method treats interstitial lung disease (ILD).ILD covers a large class and different types of lung diseases that overlap in its clinical manifestations and lung injury patterns.ILD is generally characterized by the destruction of distal lung parenchyma, resulting in changes in interstitial spaces, which results in clinical symptoms, such as dyspnea and cough, and results in restrictive ventilation and gas exchange defects in pulmonary function tests.ILD includes several diseases of unknown causes, and known ILDs associated with other diseases or environmental exposures. Although the causes of many ILDs are unclear, the disease is generally related to some forms of damage to alveolar epithelial cells, thereby initiating an inflammatory response associated with a repair mechanism. The damage repair process is pathologically reflected as inflammation, fibrosis or a combination of the two. The common feature of ILD is scarring (pulmonary fibrosis) and / or inflammation of the lungs. Interstitium is an interconnected fine mesh of tissue that extends through each lung, supporting the alveoli (air sacs) of the lungs. Under normal conditions, interstitium is very thin, so that it will not appear on X-rays or CT scans. All forms of ILD result in interstitial thickening, such as by inflammation, scarring or fluid accumulation. There is no single, universally accepted classification of ILDs. They can generally be classified based on their etiology (idiopathic or ILDs with a known association or cause), their clinical course (acute (short-lived), subacute, or chronic (long-term) ILDs), and based on predominant pathological features (inflammatory or fibrotic ILDs). A plethora of substances and conditions can lead to ILDs. Even so, in some cases, a cause is never discovered. These diseases without a known cause are grouped together as idiopathic interstitial pneumonias, the most common and deadly of which is idiopathic pulmonary fibrosis (IPF).

[0240] During the development of ILD (such as IPF), the accumulation of extracellular matrix components (such as collagen) and the increase of fibroblast colonies are observed. The continuous proliferation of fibroblasts is considered to be an important contributor to lung structure in IPF, including the reduction of interstitial space of alveoli. Therefore, reducing the proliferation of fibroblasts and structural collagen induced by TGF-β with LYT-100 has the potential to extend lung function in IPF. In addition to inhibiting the level of insoluble collagen induced by TGF-β, LYT-100 also inhibits secretory collagen and fibronectin β induced by TGF-β. Secretory collagen and fibronectin not only increase the formation rate of fibrotic lesions in the lungs, but these proteins also serve as ligands of integrin receptors. When integrin receptors are activated, they not only induce the proliferation of lung epithelial cells and fibroblasts, but also induce epithelial-mesenchymal transition (EMT) of lung epithelial cells together with TGF-β. EMT causes these cells to migrate to different areas of the lung. This migration is considered to be a very important contributor to the generation of new fibrotic lesions in the lungs and the progression of IPF. LYT-100 has the ability to inhibit TGF-β-induced pro-fibrotic processes and reduce basal factors that have the potential to exacerbate ongoing fibrosis.

[0241] Progressive fibrosing ILD can be divided into 3 groups based on their disease behavior and include non-progressive in nature, such as drug-induced lung disease after removal of the drug or some cases of hypersensitivity pneumonitis (HP) after removal of the trigger; progressive but stabilized by immunomodulation, such as some cases of connective tissue disease (CTD)-ILD; and progressive, despite appropriate treatment considered in individual ILDs, such as idiopathic pulmonary fibrosis (IPF).

[0242] Although IPF is the best known and prototype form of progressive fibrosing ILD (PF-ILD), there is a group of patients with different clinical ILD diagnoses except IPF, and they develop progressive fibrosing phenotypes during their disease course. These patients show many similarities with IPF patients, wherein their disease is defined by increasing the degree of pulmonary fibrosis during imaging, reducing lung function, worsening respiratory symptoms and quality of life, although treatment is carried out in individual ILD, and ultimately early mortality is similar to IPF, and FVC decline predicts the mortality of patients with these other fibrosing ILDs.

[0243] Non-limiting examples of ILD include non-idiopathic pulmonary fibrosis, idiopathic nonspecific interstitial pneumonia (iNSIP), autoimmune or connective tissue disease (CTD)-ILD, unclassifiable ILD (uILD), chronic hypersensitivity pneumonitis (HP), interstitial pneumonia with autoimmune features (IPAF), hereditary and / or familial idiopathic pulmonary fibrosis (g / fIPF), chronic sarcoidosis, exposure-related ILD, and drug-induced ILD.

[0244] In some embodiments, ILD is iNSIP or the interstitial pneumonia (IPAF) with autoimmune characteristics. In some embodiments, ILD is chronic HP. Chronic HP is a complex syndrome caused by the sensitization to inhaled antigens, which causes the abnormal immune response in small airways and lung parenchyma. Sensitivity is considered to be affected by heredity, antigen concentration and exposure frequency and immune tolerance.

[0245] In some embodiments, ILD is autoimmune or CTD-ILD.Autoimmune diseases are generally relevant to the pulmonary complications including ILD.The patient in the CTD pedigree has the risk of developing ILD.In some embodiments, autoimmune or CTD-ILD is systemic sclerosis ILD (SSc-ILD).In some embodiments, ILD is rheumatoid arthritis ILD (RA-ILD).In some embodiments, ILD is lupus-induced pulmonary fibrosis.In some embodiments, ILD is scleroderma interstitial lung disease.In some embodiments, ILD is mixed CTD-related ILD.

[0246] In some embodiments, ILD is interstitial lung disease (chILD) in children, which is a broad term for a group of rare lung diseases that can affect infants, children and teenagers. These diseases have some similar symptoms, such as chronic cough, shortness of breath and shortness of breath. These diseases also damage the lung in a similar manner. For example, they damage the tissue around the alveoli and bronchial tubes in the lungs, and sometimes directly damage the air sacs and airways. Various types of chILD can reduce lung function, reduce blood oxygen levels, and interfere with the respiratory process. In some embodiments, chILD is selected from surfactant dysfunction mutations, children's lung development disorders such as alveolar capillary dysplasia, abnormal lung growth, neuroendocrine cell hyperplasia in infancy (NEHI), pulmonary interstitial glycogen storage disease (PIG), idiopathic interstitial pneumonia (such as nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, desquamative interstitial pneumonia, lymphocytic interstitial pneumonia), alveolar hemorrhage syndrome, aspiration syndrome, hypersensitivity pneumonitis, infectious or post-infectious diseases ( obliterans), eosinophilic pneumonia, pulmonary alveolar proteinosis, pulmonary infiltrates with eosinophilia, pulmonary lymphatic disorders (lymphangiomatosis, lymphangiectasia), pulmonary vascular disease (angiomatosis), interstitial lung disease associated with a systemic disease process (such as connective tissue disease, histiocytosis, lung disease associated with malignancy, sarcoidosis, storage disease) or with a compromised immune system (such as opportunistic infections, diseases associated with therapeutic interventions, lung disease associated with lung and bone marrow transplantation, diffuse alveolar damage of unknown cause).

[0247] In some embodiments, the ILD is chronic sarcoidosis or sarcoidosis-associated pulmonary fibrosis. Sarcoidosis is an inflammatory disease characterized by the formation of granulomas in one or more organs of the body. When not checked, this chronic inflammation can lead to fibrosis. Sarcoidosis affects the lungs in about 90% of cases, but can affect almost any organ in the body.

[0248] In some embodiments, the method treats ILD, and it is the ILD related to exposure or the ILD induced by drugs.In some embodiments, the ILD related to exposure is pneumoconiosis.Pneumoconiosis is one of a group of ILD caused by breathing some types of dust particles (such as asbestos, coal or silica).In some embodiments, the ILD related to exposure is the pulmonary fibrosis induced by asbestos, the pulmonary fibrosis induced by silica, the pulmonary fibrosis induced by coal or other pulmonary fibrosis induced by other environments.

[0249] In some embodiments, ILD is acute interstitial pneumonia (AIP, also referred to as Hamman-Rich syndrome). AIP is an acute, rapidly progressive idiopathic lung disease that typically causes fulminant respiratory failure and acute respiratory distress syndrome (ARDS). In some embodiments, ILD is alveolitis, including chronic fibrosing alveolitis and fibrosing alveolitis.

[0250] In certain embodiments, ILD is the ILD (uILD) that can not be classified.Term " interstitial lung disease that can not be classified " was introduced into American Thoracic Society / European Respiratory Society ConsensusClassification of the Idiopathic Interstitial Pneumonias (IIP) in 2002, to contain the ILD subset that can not be classified within the current diagnostic framework.Abnormal classification is " can not be classified " is due to 1) insufficient or 2) inconsistent clinical, radiological and pathological data, makes specific ILD diagnosis impossible.

[0251] Many ILDs are characterized by inflammation and chronic fibrosis. The patient who suffers from certain types of chronic fibrotic ILD has the risk of developing a progressive phenotype. These diseases include but are not limited to iNSIP, uILD, autoimmune ILD, chronic sarcoidosis, HP, g / f IPF and exposure-related diseases (such as asbestosis and silicosis).

[0252] Because these various conditions of illness have similarity in pathogenesis and clinical behavior, they are increasingly described under the general term of " progressive fibrosis ILD " (PF-ILD) or " fibrosis ILD with progressive phenotype ".Progressive phenotype is histologically characterized by self-sustaining fibrosis, which is the common process of multiple conditions of illness, and it causes quality of life to deteriorate, lung function to decline and eventually leads to early death. Although the term " progressive phenotype " implies that the management of the prior art has been carried out, including, for example, using corticosteroids and / or immunosuppressive therapy, the progress of disease still occurs. One of the most common types of progressive fibrosis ILD is idiopathic pulmonary fibrosis (IPF). According to definition, IPF is the progressive fibrosis ILD of unknown cause, characterized in that lung function declines and early death. The prognosis of IPF is poor, and the median survival period after wherein diagnosis is usually estimated to be 2 years to 5 years.

[0253] PF-ILD includes non-IPF ILD in addition to IPF. Estimates based on surveys and insurance claims in the United States indicate that 18%-32% of patients diagnosed with non-IPF ILD will develop progressive fibrosis (Wijsenbeek et al. “Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management” Curr Med Res Opin 2019:1–10). In the same study, the time from symptom onset to death was estimated to be 61 months-80 months, and survival was poor but better than that of IPF. The incidence and prevalence of PF-ILD are not well defined, in part due to the heterogeneity of this group. It is estimated that approximately 140,000-250,000 people in the United States have PF-ILD, which includes IPF. Currently, no drugs are approved for the treatment of progressive fibrosing ILD, except for nintedanib and pirfenidone for the treatment of IPF. Therefore, LYT-100 has the potential for higher dosing than pirfenidone due to its enhanced tolerability and may be particularly advantageous in the treatment of PF-ILD.

[0254] In some embodiments, ILD is PF-ILD.In some embodiments, PF-ILD is iNSIP, CTD-ILD, uILD, chronic fibrosing HP, g / f IPF, sarcoidosis, exposure-related ILD or drug-induced ILD.

[0255] In some embodiments, the fibrosis-mediated lung disease or disorder is not idiopathic pulmonary fibrosis (IPF).

[0256] In treating any interstitial lung disease and other fibrosis-mediated lung diseases or conditions disclosed herein, LYT-100 is administered as disclosed above. In some embodiments, LYT-100 is administered at a total daily dose of about 825 mg to about 2475 mg (such as 825 mg, 1650 mg, or 2475 mg). In some embodiments, the administration is administered in three equal doses. In some embodiments, LYT-100 is administered in three equal doses of 550 mg each. In some embodiments, LYT-100 is administered in three equal doses of 825 mg each.

[0257] Clinical endpoints and biomarkers

[0258] In some embodiments, the efficacy of treatment can be evaluated by reference to various clinical endpoints or biomarkers indicative of fibrotic and inflammatory processes. Many of these clinical endpoints are described above with respect to specific diseases or conditions.

[0259] Suitable types of biomarkers include, but are not limited to, markers of alveolar epithelial cell damage and epithelial cell dysfunction, markers of alveolar macrophage activation, markers of TGF-β activation, markers of fibroblast proliferation and extracellular matrix production or renewal, markers of immune dysregulation, markers of ECM production and renewal. In some embodiments, the biomarker is Krebs von den Lungen-6 antigen (KL-6), surfactant protein (e.g., SP-A or SP-D), matrix metalloproteinase (e.g., MMP-1, MMP-7, MMP-8), PP1, YKL-40, IGFBP-1, TNFRSA1F, ICAM-1, IL-6, IL-8, CC chemokine ligands (e.g., CCL 16 and CCL 18), insulin-like growth factor (IGF), IGF binding protein (IGFBP), vascular endothelial growth factor (VEGF), periostin, or a combination thereof.

[0260] In any one of the methods described herein, the treatment method prevents, delays or slows the progression of impaired respiratory function in the subject. In some embodiments, the progression of ILD is delayed, slowed or suppressed.

[0261] Respiratory function, such as impaired respiratory function, can be measured using various methods. In some embodiments, respiratory function is determined by measuring the forced vital capacity (FVC) of the subject. In some embodiments, the progression of impaired respiratory function in the subject is determined by measuring the change in FVC during the treatment period.

[0262] In some embodiments, the change of FVC is measured as the rate of decline of FVC (mL). In one aspect, a method for treating ILD is provided, the method includes applying LYT-100 that a total daily dose is 825mg (applied with three same doses, 275mg each time) to a subject in need, wherein relative to a subject not receiving LYT-100, the rate of decline of FVC (mL) is lower. In one aspect, a method for treating ILD is provided, the method includes applying LYT-100 that a total daily dose is 1650mg (applied with three same doses, 550mg each time) to a subject in need, wherein relative to a subject not receiving LYT-100, the rate of decline of FVC (mL) is lower. In one aspect, a method for treating ILD is provided, the method includes applying LYT-100 that a total daily dose is 2475mg (applied with three same doses, 825mg each time) to a subject in need, wherein relative to a subject not receiving LYT-100, the rate of decline of FVC (mL) is lower. In some embodiments, the treatment period for measuring the rate of decline of FVC (mL) is at least 26 weeks. In some embodiments, the treatment period for measuring the rate of decline of FVC (mL) is at least 52 weeks. In some embodiments, the rate of decline of FVC (mL) in the treatment period of at least 26 weeks is less than the value of the rate of decline shown by subjects who did not receive LYT-100. In some embodiments, the rate of decline of FVC (mL) in the treatment period of at least 52 weeks is less than the value of the rate of decline shown by subjects who did not receive LYT-100.

[0263] In some embodiments, the change of FVC is measured as the change (FVCpp) of predicted FVC%. In some embodiments, the change of FVC is measured as the decline (FVCpp) of predicted FVC%. In one aspect, a method for treating ILD is provided, the method includes applying LYT-100 with a total daily dose of 825mg (administered in three equal doses, 275mg each time) to a subject in need, wherein relative to a subject not receiving LYT-100, the rate of decline of FVCpp is lower. In one aspect, a method for treating ILD is provided, the method includes applying LYT-100 with a total daily dose of 1650mg (administered in three equal doses, 550mg each time) to a subject in need, wherein relative to a subject not receiving LYT-100, the rate of decline of FVCpp is lower. In one aspect, a method for treating ILD is provided, the method includes applying LYT-100 with a total daily dose of 2475mg (administered in three equal doses, 825mg each time) to a subject in need, wherein relative to a subject not receiving LYT-100, the rate of decline of FVCpp is lower.

[0264] In some embodiments, the treatment of ILD is demonstrated or shown by the time delay of ILD progress in the subject. In some embodiments, the treatment of ILD is demonstrated or shown by the slowing down of the progression rate of ILD in the subject. In any one of the methods disclosed herein, relative to the subject not receiving LYT-100, the time length of ILD progress in the subject treated with LYT-100 is longer (increase, larger). ILD progress can be determined using various methods, including by measuring the change of FVC, such as the decline of FVC mL or FVCpp. In some embodiments, IPF progress is determined by 5% or greater FVCpp decline. In some embodiments, IPF progress is determined by 10% or greater FVCpp decline. In any one of the methods disclosed herein, relative to the subject not receiving LYT-100, the time length of ILD progress in the subject treated with LYT-100 is longer (increase, larger), as determined by 5% or greater FVCpp decline. In any of the methods disclosed herein, the length of time to ILD progression is longer (increased, greater) in subjects treated with LYT-100 relative to subjects not receiving FIG. 100 , as determined by a 10% or greater decrease in FVCpp.

[0265] In any of the methods disclosed herein, the subject exhibits a longer period of hospitalization due to impaired respiratory function relative to a subject not receiving LYT-100. In some cases, the longer length of hospitalization is a longer length of initial hospitalization due to impaired respiratory function. In some cases, the longer length of hospitalization is not an initial hospitalization, for example, it is a longer length of subsequent hospitalization due to impaired respiratory function.

[0266] In any of the methods disclosed herein, the subject has a lower frequency of hospitalizations due to impaired respiratory function relative to a subject not receiving LYT-100. In any of the methods disclosed herein, the subject has a lower number of hospitalizations due to impaired respiratory function relative to a subject not receiving LYT-100. In any of the methods disclosed herein, the subject has a shorter duration of one or more hospitalizations due to impaired respiratory function relative to a subject not receiving LYT-100.

[0267] In any of the methods disclosed herein, the time period before death due to impaired respiratory function is longer for the subject relative to a subject not receiving LYT-100. In any of the methods disclosed herein, the time period before death due to IPF is longer for the subject relative to a subject not receiving LYT-100.

[0268] In any of the methods disclosed herein, the subject has a change in one or more serum biomarkers associated with impaired respiratory function relative to a subject not receiving LYT-100. In some embodiments, the serum biomarker is collagen type 4.

[0269] In any of the methods disclosed herein, the subject is treated relative to a subject not receiving LYT-100 as determined by one or more of: King's Brief Interstitial Lung Disease Questionnaire (K-BILD) total score; Saint George Respiratory Questionnaire (SGRQ-I) domain scores; EuroQol 5-Dimension (EQ5D) questionnaire scores; and cough visual analog scale (VAS).

[0270] In any of the methods disclosed herein, the subject is treated without any dose reduction in the daily dose administered during the course of treatment. In any of the methods disclosed herein, the subject is treated without any interruption or temporary cessation of treatment during the course of treatment. In any of the methods disclosed herein, the subject is treated without any discontinuation of treatment during the course of treatment.

[0271] In one aspect, a method for reducing the quantity of one or more adverse events (AE) in ILD treatment is provided, the method comprising applying the LYT-100 that a total daily dose is 825mg (applied with three same doses, each 275mg) to a subject in need. In one aspect, a method for reducing the quantity of one or more adverse events (AE) in ILD treatment is provided, the method comprising applying the LYT-100 that a total daily dose is 1650mg (applied with three same doses, each 550mg) to a subject in need. In one aspect, a method for reducing the quantity of one or more adverse events (AE) in ILD treatment is provided, the method comprising applying the LYT-100 that a total daily dose is 2475mg (applied with three same doses, each 825mg) to a subject in need.

[0272] In any one of the above methods, the one or more adverse events are gastrointestinal related adverse events selected from nausea, vomiting, abdominal pain or bloating, dyspepsia, diarrhea, loss of appetite and constipation. In any one of the above methods, the one or more adverse events are nervous system related adverse events selected from headache, dizziness and drowsiness. In any one of the above methods, the one or more adverse events are selected from fatigue, drug intolerance and photosensitivity. In any one of the above methods, the one or more adverse events are selected from AST, ALT, GGT increase and hepatotoxicity.

[0273] Pharmaceutical composition

[0274] In another aspect, a pharmaceutical composition for use in the methods described herein is provided. The pharmaceutical composition includes an active compound, such as LYT-100, and one or more pharmaceutically acceptable excipients or carriers. Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; c) humectants such as glycerol; d) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glyceryl monostearate; h) absorbents such as kaolin and bentonite; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0275] Solid compositions of similar types may also be used as fillers in soft-filled and hard-filled gelatin capsules using excipients such as lactose (lactose or milk sugar) and high molecular weight polyethylene glycols. Solid dosage forms of tablets, dragees, capsules, pills and granules with coatings and shells such as enteric coatings and other coatings known in the field of pharmaceutical formulations may be prepared. They may optionally contain opacifiers and may also have a composition that allows them to release the active ingredient only or preferentially in a delayed manner in a certain part of the intestinal tract. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of similar types may also be used as fillers in soft-filled and hard-filled gelatin capsules using excipients such as lactose (lactose or milk sugar) and high molecular weight polyethylene glycols.

[0276] Embodiments of the present disclosure may be further defined by reference to the following non-limiting examples. It will be apparent to those skilled in the art that many modifications to the materials and methods may be made without departing from the scope of the present disclosure.

[0277] example

[0278] Examples 1 and 2 provide crossover studies comparing the safety, tolerability, and pharmacokinetics of deuterated pirfenidone (LYT-100) and pirfenidone. Example 3 provides a study exploring the tolerability of deuterated pirfenidone LYT-100 in patients with COVID-19 respiratory disease. Example 4 provides a CYP isoenzyme profile of pirfenidone and LYT-100. Example 5 provides a BioMAP fibrosis panel screening study of LYT-100 and pirfenidone in a series of fibrosis biomarkers. Example 6 provides a rat lipopolysaccharide (LPS) model of systemic inflammation. Example 7 provides a streptozotocin-induced nonalcoholic steatohepatitis (NASH) mouse model. Example 8 provides a study on the inhibition of fibrosis with LYT-100 in primary mouse lung fibroblasts. Example 9 provides a study on the inhibition of collagen synthesis with LYT-100. Example 10 provides a mouse model of lymphedema. Example 11 provides a bleomycin-induced rat pulmonary fibrosis model.

[0279] Example 1: Cross-dosing study

[0280] This study was a double-blind, randomized, two-period crossover study in healthy elderly subjects to compare the safety, tolerability, and pharmacokinetics of deuteropirfenidone (LYT-100) and pirfenidone. The crossover study was conducted at a single study center in each part of the United States.

[0281] Study Description

[0282] This study was conducted in two parts: Part 1 and Part 2.

[0283] Part 1 was a randomized, double-blind, two-period crossover study in healthy elderly subjects to compare the safety, tolerability, and pharmacokinetics of deuteropirfenidone (LYT-100) (LYT-100 dosed twice daily (BID)) with pirfenidone.

[0284] Part 2 was a randomized, double-blind, two-period crossover study in healthy elderly subjects to compare the safety, tolerability, and pharmacokinetics of deuteropirfenidone (LYT-100) (LYT-100 administered three times daily (TID)) with pirfenidone.

[0285] Study End Points

[0286] Security:

[0287] - Treatment-emergent adverse events (TEAEs), including severity and relatedness to study drug)

[0288] -Physical examination

[0289] - Vital signs

[0290] -Electrocardiogram (ECG)

[0291] -Clinical laboratory parameters including hematology, serum chemistry, coagulation, and urinalysis

[0292] - New onset concomitant medications

[0293] Pharmacokinetics:

[0294] - Key PK parameters (C max,ss , C min,ss and AUC 0-24,ss Derive and compare other PK parameters.

[0295] - Key urine PK parameters (Ae) between the parent compounds (LYT-100 and pirfenidone) and the primary metabolite (5-carboxypirfenidone) t1-t2 , CL R , Fe t1-t2 Other urine PK parameters were derived and compared.

[0296] - For fed and fasted patients, LYT-100 and pirfenidone (C max,ss and AUC 0-6,ss ) food impact assessment.

[0297] Study Design

[0298] Part 1:

[0299] Part 1 was a double-blind, randomized, two-period crossover study in healthy elderly subjects to determine the safety, tolerability, and PK of LYT-100 administered twice daily (BID) for 3 days (to steady state [Days 1 to 3 and Days 11 to 13]) compared to pirfenidone administered 3 times daily (TID) for 3 days (to steady state) under fed conditions. The final single dose of study drug (LYT 100 or pirfenidone) was administered on the morning of the fourth day of each treatment period (Day 4 / Day 14) after an overnight fast of at least 8 hours to determine the effect of food on steady-state PK parameters.

[0300] Overpackaging was used to match TID dosing of pirfenidone and to match the number of LYT-100 capsules administered per dose. Therefore, during LYT-100 treatment, the mid-day dose was placebo. Pirfenidone was administered at the current marketed dose of 801 mg TID (2403 mg daily dose).

[0301] Approximately forty elderly healthy female and male adult subjects (1:1 target ratio) were randomized into 1 of 2 groups: Group 1 or Group 2, N = 20 subjects / group; minimum 8 subjects / group of each sex. Subjects in each group were randomized to the following treatment sequence: Sequence A: pirfenidone to LYT-100; Sequence B: LYT-100 to pirfenidone. Dosing is summarized in Table 8. A graphic illustration of the study design for Part 1 is shown below. Figure 1 Provided.

[0302] Table 8: Dosing schedule by group and treatment sequence (Part 1)

[0303]

[0304] The initial dose of LYT-100 for this crossover study directly comparing LYT-100 to pirfenidone in healthy adults was 850 mg BID LYT-100 (1700 mg daily dose) versus 801 mg TID pirfenidone (2403 mg daily dose). The 850 mg BID LYT-100 (1700 mg daily dose) was selected based on PK results from earlier studies. PK modeling work using data from multiple ascending dose studies and single dose crossover studies of LYT-100 and pirfenidone indicated that doses of LYT-100 of approximately 800 mg-850 mg BID (1600 mg-1700 mg daily dose) resulted in systemic exposures similar to the marketed pirfenidone dose (2403 mg daily dose). Based on these data, a randomized blinded crossover study (N=37) was conducted in healthy elderly patients, administering LYT-100 850 mg BID 3 days of feeding with pirfenidone 801 mg TID 3 days of feeding. This study was blinded to LYT-100 using a placebo daily mid-dose to match the TID pirfenidone dose. Both drugs had a single AM ​​fasting dose on Day 4. There was a 6-day washout period between drug crossovers. Based on the results of an earlier PK crossover study, the 850 mg BID dose was selected as a match to the exposure of pirfenidone, which indicated that the steady-state systemic exposure of the 850 mg BID daily dose of LYT-100 was approximately 102% of the steady-state systemic exposure of pirfenidone administered daily at 801 mg TID.

[0305] Part 2:

[0306] Part 2 was a double-blind, randomized, two-period crossover study in healthy elderly subjects to determine the safety, tolerability, and PK of LYT-100 administered three times a day (TID) for 3 days (to steady state [Days 1 to 3 and Days 11 to 13]) compared to pirfenidone administered TID for 3 days (to steady state) under fed conditions. On the morning of the fourth day of each treatment period (Day 4 / Day 14), a final single dose of study drug (LYT-100 or pirfenidone) was administered after at least 8 hours of overnight fasting to determine the effect of food on steady-state PK parameters. Overpackaging was used to maintain study blinding. Screening was performed 28 days before the first dose of LYT-100 / pirfenidone was administered. Only subjects who met all applicable inclusion criteria and had no applicable exclusion criteria were randomized. Approximately 50 healthy elderly female and male adult subjects (1:1 ratio) were randomly divided into 1 of 2 groups: Group 1 or Group 2, N = approximately 25 subjects / group. Subjects in each group were randomized to the following treatment sequence:

[0307] Sequence A: Pirfenidone to LYT-100

[0308] Sequence B: LYT-100 to pirfenidone

[0309] A graphic illustration of the study design for Part 2 is shown below. Figure 2 Dosing is summarized in Table 9.

[0310] Table 9: Dosing schedule by group and treatment sequence (Part 2)

[0311]

[0312] ^Pirfenidone: AM dose: 3×267 mg, midday dose: 3×267 mg, PM dose: 3×267 mg. Each of the AM, midday, and PM doses was over-capped to maintain study blinding. Placebo capsules were administered as needed to match the number of LYT-100 capsules to maintain blinding. Each cohort started simultaneously or was closely staggered.

[0313] The LYT-100 dose for this crossover study directly comparing LYT-100 to pirfenidone in healthy adults was 550 mg TID LYT-100 (1650 mg daily dose) versus 801 mg TID pirfenidone (2403 mg daily dose). The 550 mg TID LYT-100 (1650 mg daily dose) was selected based on PK results from earlier studies and PK results obtained in Part 1 of this study. PK modeling work using data from multiple ascending dose studies of LYT-100 and pirfenidone, a single dose crossover study, and Part 1 of this study indicated that the LYT-100 dose of 550 mg TID (1650 mg daily dose) resulted in systemic exposures similar to the commercially available pirfenidone dose (2403 mg daily dose). Specifically, it is expected that a dose of 550 TID LYT-100 (1650 mg total daily dose) will achieve a steady-state systemic exposure that is approximately 99% of the steady-state systemic exposure observed for pirfenidone dosed at 801 mg TID.

[0314] Based on these data, a randomized blinded crossover study was conducted in healthy elderly subjects (N=49) administering LYT-100 550 mg TID 3 days fed with pirfenidone 801 mg TID 3 days fed. Both drugs had a single AM ​​fasting dose on Day 4. There was a 6-day washout period between drug crossovers. Based on the results of an earlier PK crossover study, the 550 mg TID dose was selected as a match to pirfenidone exposure.

[0315] See also Figure 3 and Figure 4 , which showed that the predicted steady-state systemic exposure (AUC24ss) of LYT-100 administered at 550 TID was 98.5% of the steady-state systemic exposure (AUC24ss) of pirfenidone administered at 801 mg TID. However, surprisingly, the predicted C max The pirfenidone C was lower than that produced by pirfenidone administered at 801 mg TID. max . Figure 4 The predicted steady-state C of LYT-100 given at 550 mg TID is shown. max The steady-state C of pirfenidone given at 801 mg TID is max Without wishing to be bound by any particular theory, it is believed that the lower C max May contribute to the tolerability enhancement of LYT-100.

[0316] Treatment period 1 (Day -1 to Day 4) Part 1 and Part 2

[0317] Subjects were admitted to the clinical research unit (CRU) on Day -1 of treatment period 1 and were administered their assigned study medication (pirfenidone or LYT-100, with or without matching placebo) every 6 hours under fed conditions for 3 days until steady state (Day 1 to Day 3). Subjects were then administered a single dose of their randomized treatment (pirfenidone or LYT-100, with or without matching placebo) on the morning of Day 4 after an overnight fast of at least 8 hours. Subjects were discharged on Day 4 after successfully completing all assessments and at the discretion of the investigator.

[0318] Treatment period 2 (Day 11 to Day 14) Part 1 and Part 2

[0319] After a minimum washout period of at least 7 days, the subject returned to the CRU and was admitted on the evening of Day 10 and administered the alternative study drug (pirfenidone or LYT-100, with or without matching placebo) every 6 hours under fed conditions for 3 days (Days 11 to 13). The subject was then administered a single dose of his randomized treatment on the morning of Day 14 after an overnight fast of at least 8 hours. The subject was discharged on Day 14 after successfully completing all assessments and at the discretion of the investigator.

[0320] On Days 1 to 3 (Treatment Period 1) and Days 11 to 13 (Treatment Period 2), subjects were administered their assigned study medication TID every 6 hours ± 0.25 hours (with approximately 240 mL of non-carbonated water) 30 minutes after the start of a standardized breakfast, lunch, or dinner (6 hours apart). An evening snack was provided ≥ 3 hours after the evening study medication administration. On Days 4 (Treatment Period 1) and 14 (Treatment Period 2), subjects were administered their assigned study medication once in the morning after an overnight fast of at least 8 hours (with approximately 240 mL of non-carbonated water). No other liquids were allowed before and within 1 hour after dosing.

[0321] On feeding days, meals are provided as follows:

[0322] Breakfast: Provide meals 30 minutes before AM dosing. Breakfast should be completed within 30 minutes of the start time.

[0323] • Lunch: Meals were provided at least 4 hours after the AM study drug dose and 30 minutes before the midday dose in Part 5 (only).

[0324] Dinner: Meals were provided at least 11.5 h after the AM dose and 30 min before the PM study drug dose.

[0325] Evening Snack: Provide a snack at least 15 hours after the AM dose (at least 3 hours after the PM dose).

[0326] On fasting days, meals are served as follows:

[0327] • On Day 4 (Period 1) and Day 14 (Period 2), breakfast was provided ≥ 4 hours after study drug administration.

[0328] Number of subjects:

[0329] Part 1

[0330] Unless additional subjects were needed to support statistical analysis, the goal was to recruit approximately 40 healthy elderly female and male adult subjects (target ratio of 1:1 male:female with a minimum of 8 per group of each sex). Part 1 was conducted on N=37 subjects who completed the study.

[0331] Part 2

[0332] Unless additional subjects were needed to support statistical analysis, the goal was to recruit approximately 50 healthy older female and male adult subjects (target ratio of 1:1 male:female with a minimum of 15 / cohort of each sex). Part 1 was conducted on N=49 subjects who completed the study.

[0333] Main inclusion and exclusion criteria

[0334] Inclusion criteria:

[0335] 1. Male or female aged 60 to 80 years (inclusive) at the time of screening.

[0336] 2. The subject's body mass index (BMI) at screening is ≥18.0 and ≤35.0 kg / m 2 between.

[0337] 3. Willing and able to avoid direct whole-body sunlight exposure from 2 days before dosing and until the final study procedure. Subjects were instructed to avoid or minimize exposure to sunlight (including sunlamps), use sunscreen with SPF 50 or higher, wear clothing that protects against sunlight exposure, and avoid concomitant medications known to cause photosensitivity (including but not limited to tetracycline, doxycycline, nalidixic acid, voriconazole, amiodarone, hydrochlorothiazide, naproxen, piroxicam, chlorpromazine, and thioridazine).

[0338] Exclusion criteria:

[0339] 1. Pregnancy or breastfeeding at screening or baseline, or planning to become pregnant (self or partner) at any time during the study (including the designated follow-up period).

[0340] 2. History of malignancy or presence of malignancy at screening or baseline, except for adequately treated localized skin cancer (basal cell or squamous cell carcinoma) or carcinoma in situ of the cervix.

[0341] 3. Clinically significant infection within 28 days of the start of dosing, or infection requiring parenteral antibiotics within 3 months prior to screening. Known exposure to another person with COVID-19 within the last 14 days is also an exclusion criterion, or a positive COVID test within five days prior to dosing.

[0342] 4. Major surgery (e.g., requiring general anesthesia) within 3 months prior to screening, or surgery planned during the participant's expected participation in the study, based on the investigator's judgment.

[0343] 5. Suffering from clinically significant systemic allergic disease or a significant history of drug allergy at screening or baseline, including a history of anaphylaxis (especially reactions to general anesthetics); allergic reactions due to any drug that caused significant morbidity; previous allergic reaction to pirfenidone.

[0344] 6. Long-term use (defined as more than 14 consecutive days) of immunosuppressants or other immunomodulatory drugs within 3 months before study drug administration. Corticosteroids are allowed at the discretion of the investigator.

[0345] 7. History or presence of conditions associated with significant immunosuppression at Screening or Baseline.

[0346] 8. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at screening.

[0347] 9. Symptoms of dysphagia at screening or baseline or known difficulty swallowing capsules.

[0348] 10. Any condition at Screening or Baseline that would interfere with drug absorption (e.g., chronic diarrhea, inflammatory bowel disease, or prior gastrointestinal surgery) or any disease or condition that may affect drug metabolism or excretion, in the investigator's judgment.

[0349] 11. History of or presence of cardiac arrhythmia or congenital long QT syndrome at screening or baseline.

[0350] 12. QT interval corrected using Fridericia's formula (QTcF) >450 milliseconds. An ECG may be repeated at Screening 30 to 60 minutes after the first ECG collected. If the repeat ECG is ≤450 milliseconds, the second ECG may be used to determine patient eligibility. However, if the repeat ECG confirms that the QTcF is still >450 milliseconds, the subject is not eligible.

[0351] 13. Use of tobacco or nicotine-containing products within 3 months prior to dosing or positive urine cotinine test at screening or baseline.

[0352] 14. Unwilling to give up consumption of tobacco or nicotine-containing products throughout the study period and until completion of the final follow-up visit.

[0353] 15. Regular drinking was defined as >21 units of alcohol per week (where 1 unit = 284 mL of beer, 25 mL of 40% alcohol, or a glass of 125 mL of wine) or the participant was unwilling to abstain from drinking 48 hours before admission and 48 hours before the study visit.

[0354] 16. Use of any of the following drugs within 30 days prior to study drug administration or within 5 half-lives of the drug (whichever is longer):

[0355] a. Fluvoxamine, enoxacin, ciprofloxacin;

[0356] b. Other CYP1A2 inhibitors (including but not limited to methoxsalen or mexiletine);

[0357] c. Contraceptive pills containing estradiol, ethinyl estradiol or gestodene;

[0358] d. Inducers of CYP1A2 (such as phenytoin), CYP2C9 or 2C19 (including but not limited to carbamazepine or rifampicin);

[0359] e. Any drug associated with QTc interval prolongation (including but not limited to moxifloxacin, quinidine, procainamide, amiodarone, sotalol).

[0360] 17. Receipt of any live vaccine within 4 weeks prior to screening or planned within 4 weeks of administration, and any non-live vaccine (including those against COVID) within 2 weeks prior to screening or planned within 2 weeks of administration.

[0361] 18. Use of any investigational drug or device within 30 days or five half-lives prior to screening.

[0362] 19. Consumption of grapefruit, grapefruit juice, Seville orange, Seville orange juice, or any food containing these ingredients within 7 days prior to dosing, or unwillingness to abstain from these foods throughout the duration of the study.

[0363] Dosage and Mode of Administration:

[0364] This was a crossover study in which subjects received a test treatment (LYT-100) and a reference (pirfenidone). All subjects received LYT-100 (BID or TID) or pirfenidone (TID) for 3 days in each corresponding treatment period, with placebo overfilled to maintain blinding. Part 1 subjects received LYT-100 850 mg BID. Part 2 subjects received LYT-100 550 mg TID. In Parts 1 and 2, all subjects also received a single dose of LYT-100 or pirfenidone on the morning of the fourth day in each corresponding treatment period, with placebo overfilled to maintain blinding.

[0365] · LYT-100 (deuterated pirfenidone) Supplied in hard gelatin capsules. Store LYT-100 at controlled room temperature between 15°C and 25°C.

[0366] · Pirfenidone (Esbriet) Supplied as white to off-white hard gelatin capsules containing 267 mg of pirfenidone.

[0367] • Both LYT-100 and pirfenidone were over-encapsulated to maintain study blinding.

[0368] Duration of treatment:

[0369] Part 1 and Part 2

[0370] The study includes a 28-day screening period, two treatment periods (each treatment period lasts 4 days), a washout period of at least 7 days between the treatment periods, and a safety follow-up visit 3 days (± 1 day) after the last dose. Therefore, the total duration of each subject's participation in the study is about 50 days. The double-blind study drug treatment for each of the two treatment periods is 4 days, for a total of 8 days.

[0371] Evaluation Criteria

[0372] Security:

[0373] Safety and tolerability were assessed by monitoring AEs, physical examinations, vital signs, 12-lead ECG, clinical laboratory values ​​(hematology panel, multiphase chemistry panel, and urinalysis), and review of concomitant treatment / medication use.

[0374] Pharmacokinetics:

[0375] Part 1 and Part 2

[0376] Subjects provided blood samples for determination of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 genotypes before treatment (i.e., Day -1 or Day 1 of treatment period 1) to support exploratory PK analysis. Subjects were required to provide consent for genotyping.

[0377] Blood samples for PK were collected from Cohort 1 and Cohort 2 at designated times during two time periods as follows:

[0378] Day 1 and Day 11: 0 (before morning dosing)

[0379] Day 2 and Day 12: No sampling

[0380] Days 3 and 13: 0 (before morning dose), and 1, 2, 3, 4, 6 (before midday dose), 7, 8, 9, 10, 12 (before evening dose), 13, 14, 15, 16, and 17 hours after morning dose

[0381] Days 4 and 14: 0 (before morning dose), and 1, 2, 3, 4, 6 (after dose),

[0382] Plasma PK parameters for steady-state dosing (Days 1 to 3 and 11 to 13) include, but are not limited to:

[0383] AUC 0-tau,ss (Area under the time-concentration curve from time zero to tau at steady state)

[0384] AUC 0-24,ss (Area under the time-concentration curve from time zero to 24 hours at steady state)

[0385] ·λz(terminal disposition rate constant / terminal rate constant)

[0386] t1 / 2 (elimination half-life)

[0387] ·C max,ss (maximum concentration during dosing interval)

[0388] ·T max (Time to maximum concentration, as reported relative to the start of the dosing interval in which the maximum concentration occurred)

[0389] ·C min,ss (Minimum concentration during dosing interval)

[0390] ·C av,ss (Average concentration during dosing interval)

[0391] ·C max,ss -C min,ss / C av,ss (Volatility)

[0392] ·C max,ss -C min,ss / C min,ss(swing)

[0393] PTF% (peak-to-trough fluctuation)

[0394] Plasma PK parameters used for food effect analysis (Day 4 and Day 14) included but were not limited to:

[0395] AUC 0-tau,ss (Area under the time-concentration curve from time zero to tau at steady state)

[0396] AUC 0-6,ss (Area under the time-concentration curve from time zero to 6 hours at steady state)

[0397] AUC 0-∞ (Area under the time-concentration curve from time zero to infinity) + AUC 0-∞ / D

[0398] %AUC ext (Area under the time-concentration curve extrapolated from time t to infinity, as a percentage of the total AUC)

[0399] ·λz(terminal disposition rate constant / terminal rate constant)

[0400] CL / F (apparent total clearance)

[0401] Vz / F (apparent volume of distribution)

[0402] ·T max (Time to reach maximum concentration)

[0403] ·t lag (Lag time)

[0404] Part 1 only

[0405] Urine samples for PK were collected from Cohort 1 and Cohort 2 at designated intervals during the two treatment periods as follows:

[0406] Days 1 and 11: Pre-dose (instruct subjects to empty their bladder approximately 30 minutes prior to dosing)

[0407] Day 2 and Day 12: No urine sampling

[0408] Days 3 and 13: Predose (instruct subjects to empty their bladder approximately 30 minutes prior to dosing), 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, 12 to 16 hours, and 16 to 24 hours after AM dose

[0409] Days 4 and 14: 0 to 3 hours and 3 to 6 hours after AM dose

[0410] Urine samples were collected for analysis of excretion in urine, separated at specified time intervals, and analyzed. The total urine volume collected at each interval (t1 to t2) was recorded. Urine PK parameters included but were not limited to:

[0411] ·Ae t1 / 2 (amount excreted in urine over time)

[0412] CLR (renal clearance rate)

[0413] Fraction of total body clearance (CL / F) represented by renal clearance (CLR / [CL / F])

[0414] Fet1-t2 (fraction of the administered dose excreted in urine during the dosing interval)

[0415] The study endpoints are defined as follows:

[0416] Security

[0417] -AEs (type, severity, and relevance to study drug)

[0418] -Physical examination

[0419] - Vital signs

[0420] -Electrocardiogram (ECG)

[0421] -Clinical laboratory parameters (hematology, serum chemistry, coagulation, and urinalysis)

[0422] - New onset concomitant medications

[0423] Pharmacokinetics:

[0424] - Key plasma PK parameters (C max,ss , C min,ss and AUC 0-24,ss Other plasma PK parameters will also be derived and compared.

[0425] - Key urine PK parameters (Ae) between the parent compounds (LYT-100 and pirfenidone) and the primary metabolite (5-carboxypirfenidone) t1-t2 , CL R , Fe t1-t2 Other urine PK parameters can be derived and compared.

[0426] - For fed and fasted patients, LYT-100 and pirfenidone (C max,ss and AUC 0-6,ss ) food impact assessment.

[0427] result

[0428] Part 1

[0429] It was determined that 1000 mg BID of LYT-100 provided an exposure (AUC) of LYT-100 that was greater than the pirfenidone exposure produced by administration of the approved dose of pirfenidone (801 mg TID). It was further determined based on dose prediction that a dose of LYT-100 in the range of 800 mg to 850 mg BID would provide an exposure (AUC) and maximum concentration (C max ) values, which are comparable to those of pirfenidone when administered at 801 mg TID (2403 mg per day).

[0430] Part 1 of the study was conducted in healthy elderly individuals, a relevant age group for IPF. Overall, the head-to-head crossover study in Part 1 was designed, at least in part, to evaluate the tolerability effects of reduced exposure to the major metabolite. To this end, thirty-seven subjects were randomized in a blinded crossover study to receive either 850 mg BID LYT-100 or 801 mg TID pirfenidone, with three days of feeding and the first 4 The dose was given in the morning without food. Figure 5A , 850mg BID LYT-100 parent drug C max The steady-state AUC and AUC of 850 mg BID were very similar to the parent drug of 801 mg TID pirfenidone. Specifically, the steady-state AUC of 850 mg BID was 102% AUC compared to the steady-state AUC of 801 mg TID pirfenidone, and the steady-state C max is the steady-state C of pirfenidone given at 801 mg TID max C max Fasting increases C max Exposure of the major metabolite of LYT-100 was reduced at 850 mg BID relative to exposure of the major metabolite (5-carboxypirfenidone) when pirfenidone was administered at 801 mg TID.

[0431] Adverse events encountered in each treatment group were Figure 5B The data are provided in the literature, which showed that no serious adverse events occurred in either group, and similar types of AEs were observed in both groups. There was no clinically meaningful difference in the overall AE rate between LYT-100 and pirfenidone.

[0432] refer to Figure 5B , adverse events in both groups were mainly GI and neurologic, with neurologic AEs including headache and dizziness. As mentioned above, fasting increases C max, and hypothesized to increase the overall GI AE rate. Consistent with this hypothesis, nausea was increased in both groups when the drug was administered after fasting, and the timing and duration of AEs were similar to those of C max The relevant impacts are consistent. Figure 5B As shown, and refer to Figure 5A , the results of this study showed that reducing exposure to the major metabolite did not improve tolerability.

[0433] Part 2

[0434] Part 2 was a double-blind, randomized, two-period crossover study in healthy elderly subjects to determine the safety, tolerability, and PK of LYT-100 550 mg administered three times daily (TID) for 3 days (to steady-state [Days 1 to 3 and Days 11 to 13]) compared to pirfenidone 801 mg TID for 3 days (to steady-state) under fed conditions. The final single dose of study drug (LYT-100 or pirfenidone) was administered on the morning of the fourth day of each treatment period (Day 4 / Day 14) after an overnight fast of at least 8 hours to determine the effect of food on steady-state PK parameters.

[0435] Overall, 49 subjects were enrolled and included in the safety population, 24 subjects were enrolled in sequence A, and 25 subjects were enrolled in sequence B. Five subjects (10.2%) did not complete the study. Two subjects in cohort 2 discontinued due to TEAEs (1 subject in sequence A (LYT-100) and 1 subject in sequence B (pirfenidone)). Two subjects in cohort 2 discontinued due to physician decision (1 subject in sequence A (LYT-100) and 1 subject in sequence B (pirfenidone)). One subject in cohort 1 who was randomized to sequence A withdrew consent while taking LYT-100.

[0436] The mean age of the total population was 67.7 years; the mean age of Cohort 1 and Cohort 2 was similar (68.5 and 66.9 years, respectively). The majority of subjects were female (53.1%; 52.2% in Cohort 1 and 53.8% in Cohort 2), predominantly white (81.6%), and had a mean BMI of 27.9 kg / m 2 The total mean number of days LYT-100 was administered was 4.0 days (4.0 days in Cohort 1 and 3.9 days in Cohort 2). The mean number of days pirfenidone was administered was 3.9 days (4.0 days in Cohort 1 and 3.9 days in Cohort 2).

[0437] A preliminary PK analysis was performed to assess the comparability of exposure to the parent (pirfenidone or deuteropirfenidone) and metabolite (5-carboxypirfenidone, regardless of treatment) following administration of LYT-100 relative to pirfenidone. Summary statistics for key PK parameters by analyte, fed state, and treatment are shown in Table 10. Overall, exposure to the parent drug (AUC 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 vs. 200 0-24 and C max ) is slightly lower and reaches C max The median time for LYT-100 was 3 hours, and the median time for pirfenidone was 2 hours. max It was about 20% lower and did not meet the criteria for bioequivalence. As expected, the concentration of the main metabolite was significantly lower after administration of LYT-100.

[0438] Table 10. Pharmacokinetic parameters following administration of pirfenidone or LYT-100 to subjects enrolled in Part 2

[0439]

[0440] Summary statistics are shown as T max Geometric mean (CV%) or median (min–max)

[0441] NOTE: Only subjects with sufficient concentration data for all time periods / analytes were included

[0442] The results of the bioequivalence assessment when the treatments were administered in the fed state (Day 3 or Day 13) are provided in Table 11. Although slightly lower exposures were observed following administration of LYT-100 in the fed state, the 0-24 , LYT-100 at a dose of 550 mg TID met the bioequivalence criteria because the lower and upper limits of the 90% confidence interval for the geometric mean ratio fell within the required interval of 0.8 to 1.25.

[0443] Table 11. Bioequivalence Assessment Using Data from Subjects Enrolled in Part 2

[0444] parameter <![CDATA[Geometric mean ratio (lower limit 5 % , upper limit 95 % )]]> <![CDATA[AUC 0-24 ]]> 0.866(0.831,0.901) <![CDATA[C max ]]> 0.800(0.737,0.868)

[0445] Note: Only subjects with adequate concentration data for all time periods / analytes were included. Bioequivalence evaluation was performed using the method of Chow et al. as implemented in the BE package for R

[0446] Using the aforementioned crossover data, a further simulation was performed. This simulation involved the AUC observed after administration of LYT-100 to each subject. 0-24 Dose normalization was performed to calculate the AUC expected after administration of an assumed dose of 550 mg TID0-24 Then the obtained AUC 0-24 The AUC observed after administration of pirfenidone 801 mg TID was 0-24 Comparison was made to calculate the individual ratios of LYT-100 to pirfenidone. These ratios were then evaluated using the same methods described in Chow (Design and Analysis of Bioavailability and Bioequivalence Studies; Chapman & Hall / CRC Biostatistics Series, Chapman; Hall / CRC 2008) and CDER (Guidance for Industry Statistical Approaches to Establishing Bioequivalence Center for Drug Evaluation and Research [CDER], FDA, 2001). The results of the simulation are provided in Table 12. Based on these evaluations, it is predicted that the LYT-100 dosing regimen of 550 mg TID provides a parent drug exposure comparable to pirfenidone administered at 801 mg TID.

[0447] Table 12. AUC0 after administration of hypothetical LYT-100 doses using pooled data. -24 and C max The predicted ratio (LYT-100: pirfenidone 801 mg TID).

[0448]

[0449] Adverse Event Summary

[0450] Overall, 28 subjects (57.1%) experienced at least one TEAE; 14 (30.4%) when taking LYT-100 and 23 (48.9%) when taking pirfenidone. The most common TEAEs (overall>5%) were nausea, headache, dizziness, vomiting, and somnolence. A summary of these TEAEs overall and by study drug is provided in Table 13.

[0451] Table 13. Summary of the Most Common (Overall >5%) TEAEs (Safety Population)

[0452]

[0453] The overall TEAEs for 10 subjects during LYT-100 dosing were mild (21.7%; 19 events) and moderate for 4 subjects (8.7%; 10 events). The overall TEAEs for 17 subjects during pirfenidone dosing were mild (36.2%; 42 events) and moderate for 6 subjects (12.8%; 8 events). Overall, 2 (4.1%) subjects in Cohort 2 reported TEAEs leading to study discontinuation, one while receiving LYT-100 (nausea) and one while receiving pirfenidone (headache and dizziness). No deaths or serious AEs were reported.

[0454] In this group of elderly subjects (mean age = 68) in both treatment groups (LYT-100 at 550 mg TID vs. pirfenidone at 801 mg TID, fed and fasted), the incidence of TEAEs of nausea and dizziness was significantly reduced in the LYT-100 treatment group compared to the pirfenidone group. Overall, among subjects who experienced at least one TEAE, the incidence in the LYT-100 group was significantly lower than in the pirfenidone group. Specifically, the overall incidence of TEAEs was reduced by 38% with LYT-100 compared to pirfenidone (30.4% vs. 48.9%, respectively).

[0455] Figure 6 A graphical illustration of the reduction in GI and neurological symptoms of LYT-100 at 550 mg TID compared to pirfenidone at 801 mg TID in this patient population is provided. Figure 6 , 50% fewer subjects experienced GI-related AEs with LYT-100 compared to pirfenidone (17.4% vs. 34.0%, respectively), including 50% less nausea (15.2% vs. 29.8%). Fewer subjects experienced neurological AEs with LYT-100 compared to pirfenidone (17.4% vs. 31.9%), particularly dizziness (2.2% for LYT-100 vs. 14.9% for pirfenidone). These study results show that substantially fewer subjects experienced AEs with LYT-100 compared to pirfenidone, and approximately 50% fewer subjects experienced GI-related AEs with LYT-100 compared to pirfenidone. There was no difference in the incidence of study discontinuations between treatment groups. The results suggest that in this subject population, LYT-100 at 550 mg TID is better tolerated than pirfenidone 801 mg TID.

[0456] Regarding the incidence of TEAEs under fed and fasting conditions, 8 (17.4%) LYT-100-treated subjects experienced at least 1 TEAE under fed conditions, while 8 (17.8%) experienced under fasting conditions. Ten (21.3%) pirfenidone-treated subjects under fed conditions and 17 (37.0%) subjects under fasting conditions experienced at least one TEAE. A summary of the most common TEAEs (≥±10%) for each study drug under fed and fasting conditions is provided in Table 14.

[0457] Table 14. Summary of the Most Common TEAEs (≥5%) Under Fed and Fasting Conditions (Safety Population)

[0458]

[0459] In this study, fed conditions reduced the incidence of TEAEs in both treatment groups. In addition, LYT-100 has better tolerance under both fed and fasted conditions compared to pirfenidone in these two dose groups. This improved LYT-100 tolerance also appears to be amplified in the fasted state. Without wishing to be bound by any particular theory, it is believed that the greater incidence of TEAEs experienced by fasting subjects in the two treatment groups may be related to the higher peak plasma concentration (C max ) are causally related, the higher peak plasma concentrations being caused by their more rapid and extensive absorption during fasting periods than when taken with food. Higher C in tolerance max The causal role of max The incidence of TEAEs in both treatment groups was significantly higher than that on the feeding day. In addition, it is worth noting that C max The increase in fasting was associated with the greatest TEAE rate in the study. Overall, the head-to-head crossover study in Part 2 was designed, at least in part, to evaluate the efficacy of reducing maternal C max As mentioned above, the results of this study showed that reducing the parent drug C max Improved tolerance.

[0460] Example 2: LYT-100 Crossover Study - 550 and 824 mg TID

[0461] This study was a double-blind, randomized, two-period crossover study in healthy elderly subjects to compare the safety, tolerability, and pharmacokinetics of deuteropirfenidone (LYT-100) and pirfenidone. The crossover study was conducted at a single study center in each part of the United States.

[0462] Study Description

[0463] The study was a randomized, double-blind, parallel-group, placebo-controlled study in healthy elderly subjects to evaluate the safety and tolerability of a dose of LYT-100 that provided an exposure of LYT-100 that was approximately 150% of the exposure of pirfenidone when given at 801 mg TID and not to exceed 850 mg TID LYT-100, compared with placebo.

[0464] Study End Points

[0465] Security:

[0466] - Treatment-emergent adverse events (TEAEs), including severity and relatedness to study drug)

[0467] -Physical examination

[0468] - Vital signs

[0469] -Electrocardiogram (ECG)

[0470] -Clinical laboratory parameters including hematology, serum chemistry, coagulation, and urinalysis

[0471] - New onset concomitant medications

[0472] Pharmacokinetics:

[0473] - Key PK parameters (C max,ss , C min,ss and AUC 0-24,ss Other PK parameters will also be derived and compared.

[0474] - Key urine PK parameters (Ae) between the parent compounds (LYT-100 and pirfenidone) and the primary metabolite (5-carboxypirfenidone) t1-t2 , CL R , Fe t1-t2 Other urine PK parameters can be derived and compared.

[0475] - For fed and fasted patients, LYT-100 and pirfenidone (C max,ss and AUC 0-6,ss ) food impact assessment.

[0476] Study Design

[0477] This is a randomized, double-blind, parallel-group, placebo-controlled study in healthy elderly people to evaluate the safety and tolerability of high-dose LYT-100 titrated under fed conditions compared to placebo. Thirty healthy adults aged 60 to 80 years were randomized to receive LYT-100 or placebo. Compared with 550 mg placebo administered TID for 3 days to steady state, subjects were administered 550 mg LYT-100 three times a day (TID) for 3 days (to steady state [Day 1 to Day 3]). Compared with 824 mg placebo TID for 3 days to steady state, from Day 4 to Day 6, subjects were administered 824 mg LYT-100 TID for 3 days. Informed consent was obtained before the start of the study. Screening was performed 28 days before the first dose of LYT-100 / placebo was administered. Only subjects who met all applicable inclusion criteria and had no applicable exclusion criteria were randomized. The dosing schedule is summarized in Table 15.

[0478] Table 15: Dosing regimen and treatment sequence

[0479]

[0480] Number of subjects:

[0481] Thirty healthy elderly female and male subjects (target ratio of male to female was 1:1, with a minimum of 10 subjects per group for each gender)

[0482] Main inclusion and exclusion criteria

[0483] Inclusion criteria:

[0484] 1. Male or female aged 60 to 80 years (inclusive) at the time of screening.

[0485] 2. The subject's body mass index (BMI) at screening is ≥18.0 and ≤35.0 kg / m 2 between.

[0486] 3. Willing and able to avoid direct whole-body sunlight exposure from 2 days before dosing and until the final study procedure. Subjects should be instructed to avoid or minimize exposure to sunlight (including sunlamps), use sunscreen with SPF 50 or higher, wear clothing that protects against sunlight exposure, and avoid concomitant medications known to cause photosensitivity (including but not limited to tetracycline, doxycycline, nalidixic acid, voriconazole, amiodarone, hydrochlorothiazide, naproxen, piroxicam, chlorpromazine, and thioridazine).

[0487] Exclusion criteria:

[0488] 1. Pregnancy or breastfeeding at screening or baseline, or planning to become pregnant (self or partner) at any time during the study (including the designated follow-up period).

[0489] 2. History of malignancy or presence of malignancy at screening or baseline, except for adequately treated localized skin cancer (basal cell or squamous cell carcinoma) or carcinoma in situ of the cervix.

[0490] 3. Clinically significant infection within 28 days of the start of dosing, or infection requiring parenteral antibiotics within 3 months prior to screening. Known exposure to another person with COVID-19 within the last 14 days is also an exclusion criterion, or a positive COVID test within five days prior to dosing.

[0491] 4. Major surgery (e.g., requiring general anesthesia) within 3 months prior to screening, or surgery planned during the participant's expected participation in the study, based on the investigator's judgment.

[0492] 5. Current clinically significant systemic allergic disease or significant history of drug allergy at screening or baseline, including history of anaphylaxis (especially reactions to general anesthetics); allergic reactions due to any drug that caused significant morbidity; previous allergic reaction to pirfenidone.

[0493] 6. Long-term use (defined as more than 14 consecutive days) of immunosuppressants or other immunomodulatory drugs within 3 months before study drug administration. Corticosteroids are allowed at the discretion of the investigator.

[0494] 7. History or presence of conditions associated with significant immunosuppression at Screening or Baseline.

[0495] 8. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at screening.

[0496] 9. Symptoms of dysphagia at screening or baseline or known difficulty swallowing capsules.

[0497] 10. Any condition at Screening or Baseline that would interfere with drug absorption (e.g., chronic diarrhea, inflammatory bowel disease, or prior gastrointestinal surgery) or any disease or condition that may affect drug metabolism or excretion, in the investigator's judgment.

[0498] 11. History of or presence of cardiac arrhythmia or congenital long QT syndrome at screening or baseline.

[0499] 12. QT interval corrected using Fridericia's formula (QTcF) >450 milliseconds. An ECG may be repeated at Screening 30 to 60 minutes after the first ECG collected. If the repeat ECG is ≤450 milliseconds, the second ECG may be used to determine patient eligibility. However, if the repeat ECG confirms that the QTcF is still >450 milliseconds, the subject is not eligible.

[0500] 13. Use of tobacco or nicotine-containing products within 3 months prior to dosing or positive urine cotinine test at screening or baseline.

[0501] 14. Unwilling to give up consumption of tobacco or nicotine-containing products throughout the study period and until completion of the final follow-up visit.

[0502] 15. Regular drinking was defined as >21 units of alcohol per week (where 1 unit = 284 mL of beer, 25 mL of 40% alcohol, or a glass of 125 mL of wine) or the participant was unwilling to abstain from drinking 48 hours before admission and 48 hours before the study visit.

[0503] 16. Use of any of the following drugs within 30 days prior to study drug administration or within 5 half-lives of the drug (whichever is longer):

[0504] a. Fluvoxamine, enoxacin, ciprofloxacin;

[0505] b. Other CYP1A2 inhibitors (including but not limited to methoxsalen or mexiletine);

[0506] c. Contraceptive pills containing estradiol, ethinyl estradiol or gestodene;

[0507] d. Inducers of CYP1A2 (such as phenytoin), CYP2C9 or 2C19 (including but not limited to carbamazepine or rifampicin);

[0508] e. Any drug associated with QTc interval prolongation (including but not limited to moxifloxacin, quinidine, procainamide, amiodarone, sotalol).

[0509] 17. Receipt of any live vaccine within 4 weeks prior to screening or planned within 4 weeks of administration, and any non-live vaccine (including those against COVID) within 2 weeks prior to screening or planned within 2 weeks of administration.

[0510] 18. Use of any investigational drug or device within 30 days or five half-lives prior to screening.

[0511] 19. Consumption of grapefruit, grapefruit juice, Seville orange, Seville orange juice, or any food containing these ingredients within 7 days prior to dosing, or unwillingness to abstain from these foods throughout the duration of the study.

[0512] Dosage and Mode of Administration:

[0513] This was a crossover study in which subjects received both the test treatment (LYT-100) and the reference (pirfenidone).

[0514] LYT-100 (deuterated pirfenidone)Supplied in hard gelatin capsules. LYT-100 should be stored at controlled room temperature between 15°C and 25°C.

[0515] Pirfenidone (Esbriet) It is supplied in white to off-white hard gelatin capsules containing 267 mg of pirfenidone. The cap of the capsule is printed with "PFD 267 mg" in brown ink. Pirfenidone should be stored at 15°C to 25°C.

[0516] · Both LYT-100 and pirfenidone were over-encapsulated to maintain study blinding.

[0517] Duration of treatment:

[0518] The study consisted of a 28-day screening period; a 6-day treatment period consisting of 3 days of up to 550 mg TID LYT-100, followed directly by 3 days of 824 mg TID LYT-100 or placebo. A safety follow-up visit was conducted 3 days (± 1 day) after the last dose. Therefore, the total duration of each subject's participation in the study was up to 40 days.

[0519] Evaluation Criteria

[0520] Security:

[0521] Safety and tolerability were assessed by monitoring AEs, physical examinations, vital signs, 12-lead ECG, clinical laboratory values ​​(hematology panel, multiphase chemistry panel, and urinalysis), and review of concomitant treatment / medication use.

[0522] Pharmacokinetics:

[0523] Subjects provided blood samples for determination of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 genotypes prior to treatment (i.e., Day -1 or Day 1) to support exploratory PK analysis. Subjects were required to provide consent for genotyping. Blood samples for PK were collected at designated times as follows:

[0524] · Day 1: 0 (before AM dose)

[0525] · Day 2: No sampling

[0526] · Day 3: 0 (before AM dose), and 1, 2, 3, 4, 6 (before midday dose), 7, 8, 9, 10, 12 (before PM dose), 13, 14, 15, 16, and 17 hours after AM dose

[0527] · Day 4: 0 (before AM dose)

[0528] · Day 5: No sampling

[0529] · Day 6: 0 (before AM dose), and 1, 2, 3, 4, 6 (before midday dose), 7, 8, 9, 10, 12 (before PM dose), 13, 14, 15, 16, and 17 hours after AM dose

[0530] · Day 7: 0 (same time as day 6 before AM dose, discharged)

[0531] The plasma concentration-time data of LYT-100 and one or more of its metabolites were analyzed using a non-compartmental approach. The plasma PK parameters of steady-state dosing (Day 1 to Day 3 and Day 4 to Day 7) included, but were not limited to:

[0532] · AUC 0-tau,ss (Area under the time-concentration curve from time zero to tau at steady state)

[0533] · AUC 0-24,ss (Area under the time-concentration curve from time zero to 24 hours at steady state)

[0534] · λ z (Terminal Disposition Rate Constant / Terminal Rate Constant)

[0535] · t 1 / 2 (Elimination half-life)

[0536] · C max,ss (maximum concentration during dosing interval)

[0537] · T max (Time to maximum concentration, as reported relative to the start of the dosing interval in which the maximum concentration occurred)

[0538] · C min,ss (Minimum concentration during dosing interval)

[0539] · C av,ss (Average concentration during dosing interval)

[0540] · C max,ss -C min,ss / C av,ss(volatility)

[0541] · C max,s sC min,ss / C min,ss (swing)

[0542] · PTF% (peak-to-valley fluctuation)

[0543] Urine samples were collected for PK at designated intervals as follows:

[0544] · Day 1 and Day 4: Predose (instruct subjects to empty their bladder approximately 30 minutes prior to dosing)

[0545] · Day 2 and Day 5: No urine sampling

[0546] · Days 3 and 6: Pre-dose (instruct subjects to empty their bladder approximately 30 minutes prior to dosing), 0 hours to 4 hours, 4 hours to 8 hours, 8 hours to 12 hours, 12 hours to 16 hours, and 16 hours to 24 hours after AM dose

[0547] Urine samples will be collected for analysis of excretion in urine, separated at specified time intervals, and analyzed. The total urine volume collected at each interval (t1 to t2) will be recorded. Urine PK parameters include, but are not limited to:

[0548] · Ae t1-t2 (amount excreted in urine over time)

[0549] · CLR (renal clearance)

[0550] · Fraction of systemic clearance (CL / F) represented by renal clearance (CLR / [CL / F])

[0551] · Fe t1-t2 (fraction of the administered dose excreted in urine during the dosing interval)

[0552] The study endpoints are defined as follows:

[0553] · Security

[0554] -AEs (type, severity, and relevance to study drug)

[0555] -Physical examination

[0556] - Vital signs

[0557] -Electrocardiogram (ECG)

[0558] -Clinical laboratory parameters (hematology, serum chemistry, coagulation, and urinalysis)

[0559] - New onset concomitant medications

[0560] · Pharmacokinetics:

[0561] - Key plasma PK parameters (C max,ss , C min,ss and AUC 0-24,ss Other plasma PK parameters were also derived and compared.

[0562] - Key urine PK parameters (Ae) between the parent compounds (LYT-100 and pirfenidone) and the primary metabolite (5-carboxypirfenidone) t1-t2 , CL R , Fe t1-t2 Other urine PK parameters can be derived and compared.

[0563] - For fed and fasted patients, LYT-100 and pirfenidone (C max,ss and AUC 0-6,ss ) food impact assessment.

[0564] Results - Pharmacokinetics

[0565] Based on the observation that lower TID doses of LYT-100 had improved tolerability compared to pirfenidone in Example 1 (but with comparable total exposure), the safety and tolerability of higher TID doses of LYT-100 were evaluated in this study (to achieve a higher overall predicted AUC or total exposure than the approved pirfenidone dose (801 mg TID), and to explore the possibility of evaluating this dose in future efficacy studies).

[0566] Subjects aged 60 to 80 years were randomized to receive LYT-100 or placebo. Subjects were administered up to 550 mg LYT-100 TID for 3 days (to steady state [Day 1 to Day 3]) compared to placebo administered TID for 3 days to steady state. Subjects were administered 824 mg LYT-100 TID for 3 days on Days 4 to 6 compared to placebo TID for 3 days to steady state. A summary of the dosing regimen is provided in Table 16.

[0567] Table 16. Dosage regimen

[0568]

[0569] Overall, 30 subjects were enrolled and included in the safety population, 24 subjects were enrolled and included in LYT-100, and 6 subjects were enrolled and included in placebo. Seven subjects (23.3%) did not complete the study. The mean age of the overall population was 64.9 years; the mean ages were similar in the LYT-100 and placebo groups, at 65.0 and 64.5 years, respectively. The majority of subjects were male (56.7%; 66.7% in the LYT-100 group and 16.7% in the placebo group). The total mean number of days of dosing with LYT-100 was 5.5 days. The mean number of days of dosing with placebo was 5.8 days.

[0570] Data of thirty subjects were obtained. All values ​​reported by eight subjects were below the quantitative level (BLQ; assuming that 6 placebo subjects plus 2 active subjects with only samples before the 1st day dose). Due to a large number of BLQ samples on the 3rd day-the 4th day and the 6th day-the 7th day, another subject was excluded. Therefore, 21 subjects have enough PK data to be used for calculating the PK parameters under lower doses (550mg TID on the 3rd day-the 4th day). Three subjects only have data on the 3rd day-the 4th day, and therefore lack the PK parameters of higher doses (824mg TID on the 6th day-the 7th day).

[0571] The results of the pharmacokinetic evaluation are provided in 7A to 18B Reference FIG. 7A to FIG. 7D , compared to the 550 mg TID dose group ( Fig. 7A and Figure 7C ), 824 mg TID dose group ( Figure 7B and Fig.7D Plasma concentrations of both parent drug (LYT-100; SD-560) and major metabolite (5-carboxypyrfenidone; SD-789) were higher in the fed state. max , AUC and T max Values ​​are provided in Figure 89. Reference Figure 8 For LYT-100, 824 mg TID and 550 mg TID doses of C max The C ratio of the metabolites was 1.45 and the AUC ratio was 1.44, demonstrating a roughly linear dose-exposure relationship. max The AUC ratios were slightly lower, at 1.32 and 1.42, respectively.

[0572] The results of this study were compared with those obtained in the previous 850 mg BID study and the previous 550 mg TID study (described in Example 1 herein). Fig.10 A and Fig.10 Although slightly lower, the AUC for the current 550 mg TID (Day 1-Day 3) study roughly matches the AUC for 550 mg TID from the previous 550 mg TID study (Part 2; solid blue and solid green lines, respectively; see also Example 1, Table 13) (LYT-100 and major metabolites, respectively), and the AUC and C for the 824 mg TID dose are similar. max Shows a significant / linear increase compared to the 550 mg TID dose.

[0573] Fig.10 A comparison of plasma concentrations of LYT-100 (administered at 550 mg and 824 mg TID) and pirfenidone (administered at 801 mg TID) versus time post-dose on Day 3 is provided. Fig.10 , the peak concentration of pirfenidone was higher than that of 550 mg LYT-100. Fig.11 A comparison of plasma concentrations of the major metabolites of LYT-100 (dosed at 550 mg and 824 mg TID) and pirfenidone (dosed at 801 mg TID) versus time after dosing on Day 3 is presented. Fig.12 A comparison of plasma concentrations versus time of pirfenidone at 801 mg TID and LYT-100 at 550 mg TID following day 3 dosing is provided.

[0574] Fig.13A The AUC of LYT-100 administered in this study and previous studies is provided 0-24 Comparison relative to body weight. Fig. 13B The AUCs of the major metabolites of LYT-100 from this and previous studies are provided 0-24 Comparison relative to body weight. Fig.13A and Fig. 13B , similar trends in weight effects were observed in all three groups, with apparent exposure differences above and below the threshold of 70kg-75kg.

[0575] Fig.14A and Fig. 14B The AUCs of LYT-100 and major metabolites from this study and previous studies are provided separately. 0-24 Comparison relative to subject age. Fig.14A and Fig. 14B , age appears to affect AUC, with exposure increasing with age.

[0576] In this dosing study and three previous dosing studies, the AUC 24ss Bioequivalence simulations were performed. The results are provided in FIG. 15A to FIG. 15D and Fig.16, which showed that bioequivalence of 550 mg TID LYT-100 to 801 mg TID pirfenidone was achieved when the combined data from the studies were used, and bioequivalence was observed for the theoretical 687 mg TID dose ( Fig.16 ). The simulation results of this study and three previous studies are provided in tabular form in Fig.17 middle. Fig.18A Illustrative predictions of plasma concentrations of pirfenidone versus time for theoretical 550 mg TID and 825 mg TID and 801 mg TID dosing of LYT-100 are provided. Fig.18A For 550 mg TID dosing, LYT-100 is predicted to achieve a maximum plasma concentration (Cmax) less than that achieved with 801 mg TID dosing for pirfenidone, but with similar exposure (AUC). In contrast, with 825 mg TID dosing, LYT-100 is predicted to achieve a Cmax only slightly greater than that achieved with 801 mg TID dosing for pirfenidone, but with a higher AUC. The estimated Cmax to AUC ratios of LYT-100 to pirfenidone are provided in Fig.18B middle.

[0577] Results - Tolerance

[0578] Four subjects discontinued due to TEAEs (3 (12.5%) subjects in the LYT-100 group and 1 (16.7%) subject in the placebo group). Three (12.5%) subjects withdrew consent; all were in the LYT-100 group. Overall, 9 subjects (30.0%) experienced at least one TEAE; 8 (33.3%) while taking LYT-100 and 1 (16.7%) while taking placebo. The most common TEAEs (overall >5%) were COVID-19 and headache. A summary of these TEAEs overall and by study drug is provided in Table 17.

[0579] Table 17. Summary of the Most Common (Overall >5%) TEAEs (Safety Population)

[0580]

[0581] A summary of TEAEs stratified by onset of Day 1-3 or Day 4-6 showed that the onset of COVID-19 events occurred within Day 4-6; the onset of headache events occurred within Day 1-3. Overall, most TEAEs were considered mild. Eight (26.7%) subjects reported 13 mild events, seven (29.2%) in the LYT-100 group, and one (16.7%) in the placebo group. One (3.3%) subject reported two moderate TEAEs; this subject was in the LYT-100 group. No TEAEs were severe. Five (16.7%) events were not related to the TEAE, and six (13.3%) events were possibly related. No events were possibly related. Overall, four (13.3%) subjects reported TEAEs that led to study discontinuation; all were Covid-19. Of these 4 TEAEs, 3 (12.5%) occurred in the LYT-100 group and 1 (16.7%) occurred in the placebo group.No deaths or SAEs were reported during the study.

[0582] Based on previous PK modeling studies, the AUC of LYT-100 at 824 mg TID is expected to be approximately 150% of the AUC of the approved 801 mg TID pirfenidone dose. In the 824 mg TID LYT-100 group (mean age = 65), this dose was well tolerated within 3 treatment days. In this dose group, the most common TEAE was headache, and most events were mild.

[0583] Using the aforementioned crossover data, a further simulation was performed. This simulation involved the AUC observed after administration of LYT-100 to each subject. 0-24 Dose normalization was performed to calculate the expected AUC after administration of various assumed TID doses. 0-24 Then the obtained AUC 0-24 The AUC observed after administration of pirfenidone 801 mg TID was 0-24The ratios of LYT-100 and pirfenidone were compared to calculate the individual ratios of LYT-100 and pirfenidone. These ratios were then evaluated using the same methods described in Chow (Design and Analysis of Bioavailability and Bioequivalence Studies; Chapman & Hall / CRC Biostatistics Series, Chapman; Hall / CRC 2008) and CDER (Guidance for Industry Statistical Approaches to Establishing Bioequivalence Center for Drug Evaluation and Research [CDER], FDA, 2001). The results of the simulation are provided in Table 18. Based on these evaluations, it is predicted that the LYT-100 dosing regimen of 550 mg TID provides a parent drug exposure equivalent to pirfenidone administered at 801 mg TID. It is predicted that the LYT-100 dosing regimen of 825 mg TID provides a parent drug exposure that is approximately 150% of the pirfenidone administered at 801 mg TID. Of note, the slower absorption of LYT-100 relative to pirfenidone resulted in a predicted C of 2.3 for LYT-100 at the 825 mg TID dose. max Only C max 15% higher.

[0584] As described in Example 3 below, actual and extrapolated exposure and C of LYT-100 given TID at 550 mg and 824 mg / 825 mg max The values ​​and tolerability data support the use of these two doses to study efficacy, safety, and dose-response in idiopathic pulmonary fibrosis.

[0585] Table 18. AUC after administration of various actual and hypothetical LYT-100 doses using the pooled data. 0-24 and C max x Predicted ratio of (LYT-100: pirfenidone 801 mg TID)

[0586]

[0587] Example 3: LYT-100 Tolerability in Patients with COVID-19 Respiratory Disease

[0588] A phase 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled trial was conducted to evaluate the safety and efficacy of deuteropirfenidone (LYT-100) compared with adult patients after the acute phase of COVID-19 respiratory disease who were treated with supplemental oxygen (including MV, ECMO or any other oxygen administration means) in the hospital for at least 1 day and only required low-flow nasal oxygen or no oxygen supplementation for at least 72 hours before screening. Patients received LYT-100 (deuteropirfenidone), which was formulated as a powder in 250mg capsules or a matching placebo. Administration is provided in Table 19. An initial dose of 500mg BID was given in the first 3 days of administration, followed by 750mg BID. Patients took LYT-100 study drug or placebo (Part A) orally, and preferably in the presence of food (solid or nutritional supplements, whenever possible), with an interval of about 10 to 12 hours between two daily doses.

[0589] Table 19: Dosage regimen

[0590]

[0591] The study enrolled 177 patients with a mean age of 55 years who experienced persistent respiratory complications requiring supplemental oxygen after hospitalization for acute COVID-19 infection and were randomized 1:1 to receive LYT-100 or placebo. Baseline demographic characteristics of the enrolled subjects and subject disposition are provided in Figures 19 to 21 middle.

[0592] Tolerability results

[0593] LYT-100 was well tolerated in this relatively ill patient population with multiple comorbidities and concomitant medications. There were no drug-related serious adverse events (SAEs) or deaths. The AEs that occurred during treatment at a frequency of greater than or equal to 5% in the LYT-100 group are summarized in Table 20. With reference to Table 20, nausea was the only AE that was judged to be at least possibly related to LYT-100, with an incidence of ≥5% (8.7% relative to 2.4% of placebo). With further reference to Table 20, other AEs that were commonly associated with pirfenidone in this study and were considered at least possibly related to LYT-100 treatment included headache (4.3% relative to 1.2% of placebo), dizziness (3.3% relative to 1.2% of placebo), fatigue (2.2% relative to 0% of placebo), and rash (3.3% relative to 1.2% of placebo). The rate of discontinuation due to AEs judged to be at least possibly related to LYT-100 was low in both groups (8.6% in the LYT-100 group and 2.4% in the placebo group), and the majority of discontinuations in the LYT-100 group were due to specific events rather than AEs generally associated with pirfenidone. A summary of all treatment-emergent adverse events judged to be at least possibly related to LYT-100 is shown in Fig. 22 Provided.

[0594] Table 20: Treatment-emergent AEs (≥5%) occurring in LYT-100

[0595]

[0596] Overall, the results of this study with respect to safety and tolerability reconfirm the strong safety and tolerability profile of LYT-100 observed in previous studies, including those described herein in Examples 1 and 2. The safety and tolerability of the 750 mg BID dose in this relatively sick patient population suggests that it may be equally well tolerated in other patient populations, such as those with interstitial lung disease or other fibrosis-mediated lung diseases.

[0597] Example 4: In vitro stability of pirfenidone and LYT-100 in the presence of recombinant human CYP isozymes

[0598] To evaluate the metabolism of LYT-100 by isolated CYP isozyme preparations and compare it with the metabolism of pirfenidone ( Fig. 27 Pirfenidone and LYT100 were each incubated with recombinant human CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 expressed in a heterologous cell system. The half-life (t1 / 2) of each test article was determined.

[0599] refer to Fig.23During incubation with recombinantly expressed human CYP1A2, CYP2D6, and CYP2C19 isozymes, pirfenidone and LYT-100 concentrations decreased by at least 15%. 1 / 2 The t values ​​of LYT-100 after incubation with CYP1A2, CYP2C19 and CYP2D6 were 3.18 hours, 2.13 hours and 2.30 hours respectively. 1 / 2 t was 9.08 h, 3.67 h, and 2.72 h, respectively. There was no significant metabolism by the CYP2C8, CYP2C9, CYP3A4, or CYP3A5 isozymes, with more than 92% of the compound remaining at the end of the incubation. Therefore, t was not calculated for those isozymes. 1 / 2 These results confirm the metabolic stability of LYT-100 compared to pirfenidone. Metabolism by CYP1A2 is most affected by deuteration (t 1 / 2 This result indicates the effect of deuteration of LYT-100 on the overall metabolism of pirfenidone, as the CYP1A2 isozyme plays a key role in the metabolism of pirfenidone.

[0600] Example 5: Activity screening

[0601] LYT-100 and pirfenidone were evaluated using the DiscoverX BioMAP Fibrosis Panel. This panel contains 54 biomarker (cell surface receptors, cytokines, chemokines, matrix molecules, and enzymes) readouts that capture biological changes that occur in the physiological environment of a specific BioMAP system. LYT-100 and pirfenidone were tested in the BioMAP Fibrosis Panel in three cell / stimulant systems (myofibroblasts [MyoF], which are composed of lung fibroblasts treated with TNF-a and TGF-β; renal proximal tubular epithelial cells (RE) MyoF, which include renal tubular epithelial cells and lung fibroblasts treated with TNF-a and TGF-β; and small airway epithelial cells (SAE) MyoF, which include small airway epithelial cells and lung fibroblasts treated with TNF-a and TGF-β) at various dilutions starting with the highest dose of 1700 μM. Similar results were observed for the two compounds in the three systems ( Fig.24 ).

[0602] Example 6: Effect of oral dose of LYT-100 on lipopolysaccharide (LPS)-induced Inhibition of plasma TNF-α and IL-6 concentrations

[0603] LYT-100 and pirfenidone dosing solutions were prepared by dissolving each in a vehicle of 1% carboxymethylcellulose and 0.2% Tween-80 aqueous solution. LPS was diluted to 2 mg / mL with sterile saline and sonicated at 40°C for 20 minutes to produce a stock solution and stored at 4°C. The stock solution was further diluted to 0.03 mg / mL in sterile saline for daily use.

[0604] Male Sprague-Dawley rats (n=6-8 / dose and test article group) with indwelling femoral and jugular vein catheters were used in this study. Rats were administered 30 mg / kg, 100 mg / kg, or 300 mg / kg concentrations of vehicle (dosing solution, 10 mL / kg), LYT-100, or pirfenidone via a syringe connected to an oral gavage needle. Sixty minutes after oral administration, 1 mL / kg saline containing 0.03 mg / kg LPS was infused into the jugular vein.

[0605] Blood samples were collected from the femoral vein into heparin-coated syringes 15 minutes before LPS infusion (45 minutes after oral test article dose), 90 minutes after LPS infusion, and 4 hours after LPS infusion. Plasma was prepared by centrifugation of blood samples at 14,000 rpm for 10 minutes. Plasma samples were stored at -70°C until analysis.

[0606] LPS stimulates a strong inflammatory response, including the cytokines TNF-α and IL-6 ( Fig.25A and Fig.25B ). refer to Fig.25A , in vehicle pretreated rats, LPS increased plasma TNF-α concentrations from undetectable concentrations to approximately 75,000 pg / mL 90 minutes after injection). This TNF-α response to LPS was reduced by pretreatment with pirfenidone and LYT-100. Ninety minutes after LPS injection, pretreatment with LYT-100 at oral doses of 100 mg / kg and 300 mg / kg inhibited TNFα. At 100 mg / kg, TNF-α levels were 70% lower than those obtained with an equivalent oral volume of vehicle control, and the reduction in TNF-α response was greater in rats pretreated with LYT-100 compared with pirfenidone (Tables 21, 22, and Fig.25A Pretreatment with LYT-100 at oral doses of 100 mg / kg and 300 mg / kg also inhibited IL-6 similarly to pirfenidone (Tables 23, 24, and Fig.25B ). Thus, LYT-100 retains the activity of pirfenidone in attenuating LPS-induced TNF-α and shows additional potency at equivalent doses, which may be due to the pharmacokinetic effect of deuteration.

[0607] Table 21. Pretreatment with vehicle, pirfenidone or LYT-100 orally and intravenous LPS (1.5 h after LPS) Plasma TNFα concentration (pg / ml)

[0608]

[0609]

[0610] a Data represent mean standard deviation; n = 6-8 / group

[0611] Table 22. Pretreatment with vehicle, pirfenidone or LYT-100 orally and intravenous LPS (4 h after LPS) Plasma TNFα concentration (pg / ml)

[0612]

[0613] a Data represent mean standard deviation; n = 6-8 / group

[0614] Table 23. Pretreatment with vehicle, pirfenidone or LYT-100 orally and intravenous LPS (1.5 h after LPS) Plasma IL-6 concentration at 24h

[0615]

[0616] a Data represent mean standard deviation; n = 6-8 / group

[0617] Table 24. Results of the studies following oral pretreatment with vehicle, pirfenidone, or LYT-100 and intravenous LPS (4 h after LPS) Plasma IL-6 concentration at 24h

[0618]

[0619] a Data represent mean standard deviation; n = 6-8 / group

[0620] Example 7: LYT-100 significantly reduces the area of ​​fibrosis in a mouse model

[0621] Nonalcoholic fatty hepatitis (NASH) is characterized by lobular inflammation, hepatocyte ballooning, and degeneration that progresses to liver fibrosis. LYT-100 was orally administered to 18 6-9 week old male mice at 0 mL / kg (vehicle only: 0.5% carboxymethyl cellulose) or 10 mL / kg twice a day, wherein NASH mice were induced by a single subcutaneous injection of 200 μg streptozotocin solution 2 days after birth and fed with a high fat diet after 4 weeks of age. LYT-100 was administered twice a day at an oral dose of 30 mg / kg (60 mg / kg / day). In addition, nine non-NASH mice were fed a normal diet and monitored.

[0622] Fig.26Representative photomicrographs of liver sections stained with Sirius red are depicted, which illustrate that LYT-100 significantly reduces the area of ​​fibrosis. Specifically, liver sections from the vehicle group showed collagen deposition in the central pericentral region of the liver lobules. In addition, the LYT-100 group showed a significant reduction in the area of ​​fibrosis compared to the vehicle group. These results demonstrate that LYT-100 has the potential to inhibit the progression of fibrosis. Fig. 27 The percentage of fibrosis area for LYT-100 relative to vehicle and control is plotted. The results are also summarized in Table 25 below.

[0623] Table 25: Fibrosis Area

[0624] parameter normal vehicle LYT-100 (mean ± SD) (n=9) (n=7) (n=8) Fibrosis area (%) 0.27±0.06 1.02±0.20 0.64±0.31*

[0625] *p<0.01, vehicle vs. LYT-100

[0626] Liver sections of the vehicle group showed severe microvesicular and macrovesicular fat deposition, hepatocyte ballooning, and inflammatory cell infiltration. Although LYT-100 hepatocyte ballooning was similar to the vehicle, the scores for lobular inflammation and fatty degeneration were lower (Table 26). The components of the NAS score are provided in Table 27.

[0627] Table 26: NAFLD Activity Score

[0628]

[0629] Table 27. Definition of NAS components

[0630]

[0631] As demonstrated above, LYT-100 significantly reduced fibrosis area, reduced inflammation, and decreased fat accumulation (steatosis) compared to untreated NASH mice.

[0632] Example 8: LYT-100 reduces TGF-β-induced proliferation of primary mouse lung fibroblasts and collagen production level

[0633] The ability of LYT-100 to reduce TGF-β-induced proliferation and collagen levels in primary mouse lung fibroblasts (PMLF) was evaluated.

[0634] LYT-100 is important for inhibiting p38 members because p38 members are activated by the TGF-β signaling pathway. TGF-β activation plays an important role in the transcriptional induction of type IA2 collagen. Type IA2 collagen constitutes most of the extracellular matrix, which accumulates during the progression of fibrotic lung disease, for example. Collagen deposition is one of the most important components of fibrotic lung tissue, a process mainly induced by TGF-β. Since the accumulation of insoluble collagen occupies the alveolar space, it plays a key role in the deformation of lung structure and the progression of fibrotic lung disease. In addition to insoluble (structural) collagen, fibrotic lungs of IPF patients also show high levels of non-structural (soluble) collagen. Although this type of collagen can eventually become insoluble collagen, until then, soluble collagen can serve as a ligand for the integrin receptors of lung fibroblasts and epithelial cells. The binding of soluble collagen to these receptors induces the proliferation and migration of these cells. Fibronectin is another important component of fibrotic lungs because it is induced by TGF-β and acts as a structural component of the extracellular matrix (ECM) as well as a ligand for integrin receptors. Just like soluble collagen, binding of fibronectin to integrin receptors induces proliferation of fibroblasts and lung epithelial cells and plays an important role in the development of IPF. Therefore, inhibition of TGF-β-induced collagen synthesis is an important target for fibrotic lung diseases.

[0635] Preparation of primary mouse lung fibroblasts

[0636] Primary mouse lung fibroblasts were prepared as follows. One lung was removed from a 2-month-old male BalbC mouse, perfused with sterile PBS, minced and incubated at 37°C for one hour in 2 ml serum-free Dulbecco's Modified Eagle's Medium (DMEM) containing 100 μg / ml collagenase I. Each sample was centrifuged at 1500 r.pm (revolutions per minute) for 5 minutes, washed three times with PBS, and the final cell pellet was resuspended in DMEM supplemented with 10% serum and Pen / Strep, and incubated in 150 mm plates at 37°C with 80% humidity and %% CO2. Growth medium was removed, and fresh medium was added every day for 10 days.

[0637] Testing the effect of LYT-100 on the survival of primary mouse lung fibroblasts

[0638] The ability of LYT-100 to alter TGF-β-induced PMLF proliferation was evaluated. At the end of the above 10-day incubation period, lung fibroblasts were confluent. Prior to testing the effect of LYT-100 on the survival of these cells, the fibroblasts were trypsinized and five thousand cells were plated in 200 μL complete DMEM in a 96-well plate and incubated until the cells reached 95%-100% confluence, then the medium was removed and complete DMEM containing proline (10 μM) and ascorbic acid (20 μg / ml) was added. LYT-100 dissolved in pure ethanol was added to the plate at a final concentration of 500 μM 1 h before adding TGF-β (5 ng / ml), and the cells were further incubated for 72 hours. One hundred microliters of growth medium was removed and 20 μL of MTT stock solution (prepared in PBS at a concentration of 5.5 mg / ml) was added and the cells were incubated for 4 hours before adding 100 μL of dimethyl sulfoxide and monitoring the absorbance of color development at 540-690 nm.

[0639] like Fig.28A As shown, LYT-100 alone did not affect the survival of PMLF. TGF-β (5 ng / ml) significantly induced the proliferation of PMLF by nearly 45% (p=0.001), while LYT-100 did appear to reduce TGF-β-induced PMLF proliferation by 10%, but this effect was not statistically significant (p=0.19).

[0640] TGF-β-induced insoluble collagen synthesis using a 6-well plate format

[0641] The effect of LYT-100 on the inhibition of TGF-β-induced collagen synthesis was evaluated in PMLF in a 6-well format. One hundred thousand primary mouse lung fibroblasts were plated in 6-well plates and incubated in complete DMEM until they reached confluence. The incubation medium was removed and complete DMEM containing proline (10 μM) and ascorbic acid (20 μg / ml) was added. LYT-100 was added to the plate at a final concentration of 500 μM 1 h before the addition of TGF-β (5 ng / ml), and the cells were further incubated for 72 hours.

[0642] Remove the supernatant, wash the cells with cold PBS and add 1 ml of Sircol reagent. Sircol reagent contains collagen-binding dye Sirius red. Scrape the cells with Sircol reagent, and shake the sample at room temperature (RT) for 5 h, centrifuge at 10,000 rpm for 5 min, remove the supernatant, wash the precipitate in 0.5 M acetic acid to remove unbound dye, and centrifuge again at 10,000 rpm for 5 min, remove the supernatant, dissolve the final precipitate in 1 ml of 0.5 M NaOH, and shake at RT for 5 h. Samples of 100 μl of the resulting solution are placed in 96 wells. The color reaction is evaluated by the optical density at a wavelength of 600 nm.

[0643] like Fig.28B As shown, PMLF responded to TGF-β and total collagen levels increased (21% increase; p=0.0087). LYT-100 inhibited this induction by 15% (p=0.026) compared to TGF-β alone, without reducing background levels of collagen.

[0644] TGF-β-induced insoluble collagen synthesis using a 96-well plate format

[0645] The effect of LYT-100 on TGF-β-induced collagen was confirmed in a high-throughput collagen assay using a 96-well plate format. Approximately 5,000 primary mouse fibroblasts were plated in complete DMEM in a 96-well plate and incubated for 3 days, at which time the culture reached confluence. After the cells reached confluence, the culture medium was removed and fresh DMEM supplemented with ascorbic acid (20 μg / ml) and proline (10 μMol) was added. LYT-100 was then added to the appropriate culture at a final culture concentration of 500 μM. One hour later, TGF-β was added to the appropriate culture at a final concentration of 5 ng / ml. After 72 hours, the culture medium was replaced with a 0.5% glutaraldehyde solution. After 30 minutes, the adherent cells were washed and subsequently incubated with acetic acid at a final concentration of 0.5 M. After incubation at room temperature for 30 min and subsequent washing steps, the wells were incubated with Sircol reagent. After 5 hours, unbound dye was removed and the plates were washed and dried. To extract collagen-bound Sircol, 100 μL of alkaline solution (0.5 M NaOH) was added and the plates were shaken on a rotary shaker at room temperature for 1 h. The absorbance at 600 nm was measured to detect bound collagen.

[0646] like Fig.28C As shown, in a 6-well format, TGF-β induced insoluble collagen levels by 40% (p=0.0002) and LYT-100 reduced this TGF-β stimulated collagen accumulation by 24% (p=0.0003) without reducing background levels of collagen.

[0647] TGF-β-induced soluble fibronectin and collagen synthesis

[0648] The ability of LYT-100 to alter TGF-β-induced soluble fibronectin and soluble collagen synthesis was evaluated using a selective ELISA. Approximately 5,000 primary mouse lung fibroblasts were plated in complete DMEM in a 96-well plate and incubated for 3 days, when the culture reached confluence. After the cells reached confluence, the culture medium was removed and fresh DMEM supplemented with ascorbic acid (20 μg / ml) and proline (10 μM) was added. LYT-100 was then added to the appropriate culture at a final culture concentration of 500 μM. One hour later, TGF-β (5 ng / ml) was added to the appropriate culture at a final concentration. After 72 hours, 200 μl supernatant samples were placed on an ELISA plate and incubated overnight. After blocking with 1% BSA for 2 h, the plate was incubated with anti-type I collagen antibody or anti-fibronectin antibody.

[0649] After 1 hour, the plate was washed and incubated with horseradish peroxidase-conjugated secondary antibodies (anti-goat antibody for collagen antibody, anti-rabbit antibody for fibronectin antibody). After a series of washing steps, the color developer TMB (3,3',5,5'-tetramethylbenzidine) was added, and after 15 minutes, the reaction was stopped with an equal volume of 2N H2SO4. The levels of soluble collagen and fibronectin were determined by evaluating the absorbance at 450nm.

[0650] refer to Fig.28D , TGF-β induced soluble fibronectin levels by 16% (p=0.0021). LYT-100 inhibited TGF-β-dependent fibronectin induction by 11% (p=0.0185). In addition, LYT-100 also inhibited background levels of soluble fibronectin by 10% (p=0.03).

[0651] like Fig.28E As shown, TGF-β induced soluble collagen levels by 20% (p=0.0185). LYT-100 inhibited this TGF-β-dependent increase by 36% (p=0.0001). In addition, it also inhibited background levels of soluble collagen by 23% (p=0.0115).

[0652] In summary, LYT-100 was found to: (i) reduce TGF-β-induced cell proliferation, (ii) reduce background and TGF-β-induced insoluble (structural) collagen levels; (iii) reduce both background and TGF-β-induced soluble collagen levels; and (iv) reduce both background and TGF-β-induced soluble fibronectin levels.

[0653] During the development of fibrotic lung disease (such as IPF), the accumulation of extracellular matrix components (such as collagen) and the increase of fibroblast colonies were observed. The continuous proliferation of fibroblasts is considered to be an important contributor to lung structure in fibrotic lung disease, including the reduction of interstitial space of alveoli. Therefore, reducing the proliferation of fibroblasts and structural collagen induced by TGF-β with LYT-100 has the potential to prolong lung function in fibrotic lung disease. In addition to inhibiting the level of insoluble collagen induced by TGF-β, LYT-100 also inhibits secretory collagen and fibronectin β induced by TGF-β. Secretory collagen and fibronectin not only increase the formation rate of fibrotic lesions in the lung, but these proteins also serve as ligands of integrin receptors. When integrin receptors are activated, they not only induce the proliferation of lung epithelial cells and fibroblasts, but they also induce epithelial-mesenchymal transition (EMT) of lung epithelial cells together with TGF-β. EMT makes these cells migrate to different areas of the lung. This migration is considered to be a very important contributor to the generation of new fibrotic foci in the lung and the progression of fibrotic lung diseases such as IPF.LYT-100 has the ability to inhibit TGF-β-induced pro-fibrotic processes and reduce basal factors that have the potential to exacerbate ongoing fibrosis.

[0654] Example 9: Effect of LYT-100 on L929 cells

[0655] The effect of LYT-100 on L929 cell survival was determined. Five thousand L929 cells were plated in complete DMEN and incubated for 3 days until confluence. The culture medium was removed and complete DMEM containing proline (20 μg / ml) and ascorbic acid (10 uM) was added. LYT-100 was given at 500 μM 1 h before the addition of TGFβ (5 ng / ml), and the cells were further incubated for 72 hours. An aliquot of 100 μL of culture medium was removed, 20 μL of MTT solution was added for 4 hours, then 100 μl of DMSO was added, and the absorbance of the developed dark pink color was measured at 54 nM-690 nM. Fig.29A Showing that LYT-100 does not affect L929 cell survival.

[0656] The effect of LYT-100 on TGF-induced collagen synthesis in a 6-well format was determined. 100,000 L929 cells were plated in complete DMEM and incubated for 3 days until confluence. The medium was removed and complete DMEM containing proline (20 μg / ml) and ascorbic acid (10 μM) was added. LYT-100 was added at 500 μM 1 hour before the addition of TGF-β (5 ng / ml). The cells were further incubated for 72 hours. The supernatant was removed, the cells were washed with cold PBS, 1 ml of Sircol reagent was added to the cells and the cells were scraped off, the samples were shaken at room temperature for 5 h, centrifuged at 10,000 rpm for 5 min, the supernatant was removed, the pellet was dissolved in 0.5 M acetic acid to remove unbound dye, and centrifuged again at 10,000 rpm for 5 min, the supernatant was removed and the final pellet was dissolved in 1 ml of 0.5 M NaOH, shaken at room temperature for 5 h, 100 μl of the resulting solution was placed in a 96-well and the absorbance was measured at 600 nM. The results are summarized in Fig.29B , which demonstrates that LYT-100 inhibits TGF-induced collagen synthesis. LYT-100 also significantly inhibits collagen synthesis in the absence of added TGF-β.

[0657] Next, the effect of LYT-100 on TGF-induced collagen synthesis was confirmed using a 96-well plate format. Five thousand L929 cells were plated in complete DMEN and incubated for 3 days until confluence. The culture medium was removed and complete DMEM containing proline (20 μg / ml) and ascorbic acid (10 μM) was added. LYT-100 was added at 500 μM 1 h before adding TGF-β (5 ng / ml). The cells were further incubated for 72 hours. The supernatant was removed, 0.5% glutaraldehyde was added at room temperature for 30 min, removed, washed 3x with water, 0.5 M acetic acid was added at room temperature for 30 min, removed, washed with water, air dried and 100 μl Sircol dye was added at room temperature for 5 h. The dye was removed, the plate was washed thoroughly under running water, air dried, and 200 μl 0.5 M NaOH was added, the plate was shaken at room temperature for 1 h, and the absorbance was measured at 600 nm. Fig.29C The results summarized in 24 indicate that LYT-100 significantly inhibits or reduces the total collagen level induced by TGF-β. In the absence of TGF-β induction, LYT-100 also significantly inhibits or reduces the total collagen level.

[0658] The effect of LYT-100 on TGF-induced soluble collagen synthesis was determined using a 96-well plate format. Five thousand L929 cells were plated in complete DMEN and incubated for 3 days until confluence. The culture medium was removed and complete DMEM containing proline (20 μg / ml) and ascorbic acid (10 μM) was added. LYT-100 was added at 500 μM 1 h before adding TGF-β (5 ng / ml). The cells were further incubated for 72 hours. 200 μl of supernatant from a 96-well Sircol plate was placed on an ELISA plate and incubated overnight. The next day, the supernatant was removed, and 100 μl of 1% BSA in PBST was added and incubated at room temperature for 2 h, BSA was removed, the plate was washed 3x with 200 μl PBST, and type I anti-collagen antibody (prepared in 1% BSA in PBST) was added at a dilution of 1:2000, incubated at room temperature for 1 h, the primary antibody was removed, the plate was washed 3x with 200 μl PBST, and secondary anti-goat HRP was added at a dilution of 1:2000, incubated at room temperature for 1 h, removed, the plate was washed 3x with 200 μl PBST, and 100 μl TMB solution was added for color development for 15 min, then 100 μl 2N H2SO4 was added to stop the reaction, and the absorbance of the developed yellow color was measured at 450 nm.

[0659] like Fig.29D As shown, LYT-100 significantly inhibited TGF-β-induced soluble collagen levels. LYT-100 also significantly reduced soluble collagen levels in the absence of TGF-β induction.

[0660] Fibronectin is another important component of the fibrotic lung, as it is induced by TGF-β and functions as a structural component of the extracellular matrix as well as a ligand for integrin receptors. As with soluble collagen, binding of fibronectin to integrin receptors induces proliferation of fibroblasts and lung epithelial cells. The effect of LYT-100 on TGF-induced soluble fibronectin synthesis was determined using a method similar to that described in the above paragraph for soluble collagen synthesis, except that a fibronectin ELISA was used. Fig.29E As shown, LYT-100 significantly reduced soluble fibronectin levels in the absence and presence of TGF-β induction.

[0661] Example 10: LYT-100 study in a lymphedema mouse model

[0662] This experiment tested the effects of LYT-100 in a mouse tail model of lymphedema. LYT-100 or control (carboxymethyl cellulose) was delivered once daily by oral gavage to mice with cleared tail lymphatics via circumferential resection and removal of collecting lymphatic trunks. The tail volume of all animals was measured weekly, starting before surgery and continuing until the appearance of COVID19, requiring the study to be terminated at 6 weeks. At the time of sacrifice, the tail was collected for histology and immunofluorescence imaging to characterize the tissue changes of surgery and LYT-100 or control treatment. The tail volume between LYT-100 and the control group and markers of lymphatic vessels, fibrosis and inflammation were compared.

[0663] Animals: 14 adult (10-14 weeks old) C57BL / 6J mice. 7 animals per group.

[0664] Surgery: A 2-mm full-thickness skin excision of the superficial and deep collecting lymphatic vessels in the middle of the tail was performed, and a subcutaneous excision was performed 15 mm from the base of the tail. Under a surgical microscope, the lymphatic vessels adjacent to the lateral vein (collecting lymphatic vessels) were identified and eliminated by controlled limited cautery. The dosage, route, and schedule are provided in Table 28.

[0665]

[0666]

[0667] The measurements are provided in Table 29.

[0668]

[0669] Study procedures and timing are provided in Table 30.

[0670]

[0671]

[0672] FIG. 30A to FIG. 30D Depicted are the results of once daily administration of LYT-100 over six weeks to reduce swelling in a mouse lymphedema model. Fig. 30A The diagram is shown in the figure. Fig. 30B As shown, daily administration of LYT-100 significantly reduced swelling by 5 weeks compared to the carboxymethylcellulose control. Fig. 30C and Fig.30D The images in depict the difference in swelling at 6 weeks.

[0673] Example 11: Evaluation of LYT-100 efficacy in a rodent bleomycin-induced fibrosis model

[0674] The rodent bleomycin-induced fibrosis model (BLM) is often used in the preclinical setting because it appears to have clinical relevance to animal models of human fibrosis (e.g., idiopathic pulmonary fibrosis) based on the lung pathophysiology observed after bleomycin challenge in rats. See, e.g., Corboz et al., Pumonary Pharm. & Ther. 49 (2018), 95-103). Bleomycin is a metabolite of the bacterium Streptomyces verticillus, first identified in 1962.

[0675] Specifically, bleomycin is a non-ribosomal hybrid peptide-polyketide natural product with the following structure:

[0676]

[0677] Although bleomycin has antibacterial activity, its toxicity prevents its use as an antibiotic. Bleomycin is used as a chemotherapeutic agent in the treatment of various cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, ovarian cancer, and cervical cancer. Bleomycin works by inducing DNA strand breaks and can also inhibit thymidine incorporation into DNA strands. Bleomycin is dependent on oxygen and metal ions for DNA cleavage, at least in vitro, although the exact mechanism of DNA strand breaks has not yet been resolved.

[0678] Common side effects associated with bleomycin chemotherapy include fever, weight loss, vomiting, rash, and severe allergic reactions. The most serious complications of bleomycin therapy that occur with increasing doses are pulmonary fibrosis and impaired lung function. At high concentrations, bleomycin induces DNA strand breaks, generates free radicals, and causes oxidative stress, leading to cell necrosis and / or apoptosis. Recent studies support a role for the proinflammatory cytokines IL-18 and IL-1β in the mechanism of bleomycin-induced lung injury. Bleomycin is normally metabolized by the enzyme bleomycin hydrolase, but the lungs are particularly susceptible to bleomycin toxicity due to the deficiency of this enzyme in the lungs. Pulmonary inflammation, fibrosis, decreased lung compliance, and impaired gas exchange are consequences of bleomycin challenge.

[0679] In evaluating the anti-fibrotic potential of a compound of interest, evaluation is usually performed at a defined fibrotic stage, i.e., 10-15 days after initiation, rather than in the early stages of bleomycin-induced inflammation. Conversion of proline to hydroxyproline and incorporation into lung collagen occurs as early as 4 days after bleomycin administration. The transition between inflammation and fibrosis occurs in rats at approximately the 9th day after bleomycin administration. It is considered ideal to evaluate the activity of LYT-100 during the inflammatory and fibrotic stages of the model. Therefore, LYT-100 was administered starting on the 8th day after bleomycin administration.

[0680] Phase I study

[0681] Initially, a Phase I study was conducted to evaluate the effects of bleomycin and LYT-100 on body and lung weights in a rat BLM-induced lung fibrosis model. The Phase I study design is provided in Table 31.

[0682] Table 31. BLM study design - Phase I

[0683]

[0684] For Groups 1, 2, and 3, bleomycin and vehicle dosing was performed as shown in Table 31 (0.45 mg / kg, 1696 IU / mg bleomycin or saline on Days 1, 2, 3, 6, and 7). On Days 8-13, LYT-100 was administered once daily by oral gavage.

[0685] Observations

[0686] Various clinical signs and symptoms of animals were observed after administration of bleomycin and LYT-100. The incidence of abnormal sounds in all animals administered bleomycin or saline on the 1st, 2nd, 3rd, 6th and 7th days was 100%, which was alleviated on the next study day, thereby confirming the administration to the lungs. From the 3rd day, respiratory signs of all animals administered bleomycin (Group 2 and Group 3) were observed, and the incidence of increased respiratory rate by the 5th day was 100%. No increase in respiratory rate was observed in Group 1. Respiratory signs are an indication of acute inflammation secondary to bleomycin attack. After the administration of LYT-100 was started on the 8th day, some animals were observed to have abnormal gait. About 5h after recording, the signs of the animals disappeared, and did not appear in the subsequent administration situation. After administration of LYT-100 on days 8, 9, and 10, almost all animals were emaciated and had reduced activity, after which point signs only appeared in Group 3 (bleomycin / 400 mg / kg LYT-100) on day 13. When this sign appeared, it disappeared about 5 h after recording. After the start of LYT-100 administration on day 8, eyelid closure was observed in all animals. About 5 h after recording, the signs of the animals disappeared and did not appear in subsequent dosing situations. After the start of LYT-100 administration on day 8, the fur of some animals in Groups 1 and 2 was observed to stand up, and it was observed again on day 11. About 5 h after recording, the signs of the animals disappeared and did not appear in subsequent dosing situations. After the start of LYT-100 administration on day 1, almost all animals were observed to secrete saliva. About 5 h after recording, the signs of the animals disappeared and did not appear in subsequent dosing situations.

[0687] result

[0688] Body and lung weights were assessed during the study to determine the effects of bleomycin and LYT-100 in the model. Weight gain was prevented in Groups 2 and 3 that received bleomycin between Days 1 and 9 ( Fig.31 ). Continue to refer to Fig.31 From day 10 and until the end of period 1 on day 14, weight gain in Groups 2 and 3 resumed at a rate similar to Group 1 receiving saline. Weight gain (expressed as % of body weight compared to minus 1 day body weight) was prevented in Groups 2 and 3 receiving bleomycin between days 1 and 9. From day 10 and until the end of period 1 on day 14, weight gain in Groups 2 and 3 resumed at a rate similar to Group 1 receiving saline.

[0689] As expected from this model, lung weights were heavier in animals treated with bleomycin (Group 1 vs. Groups 2 and 3). As expected from this model, lung weight ratios (expressed as % of body weight; Fig.32A and Fig.32B ) is heavier.

[0690] In general, according to the protocol, Phase 1 was performed, and no deviation was considered to affect the integrity of the results of this phase. During Phase 1 (tolerance), in healthy (high dose) and bleomycin-challenged (low and high dose) rats, from the 8th day until (including) the 13th day, LYT-100 was administered once a day (QD) with high (400mg / kg) and low (250mg / kg) dose levels. LYT-100 was well tolerated by all animals, and there was no obvious correlation between the dose level and the presence of side effects. Any side effects observed disappeared within about 5 hours after noticing it, and did not reappear before the subsequent administration situation. Based on the weight development, clinical signs, lung weight and lung weight to body weight ratio of animals, the tolerance stage determined that the LYT-100 administered with 400mg / kg QD was well tolerated by both healthy and bleomycin-challenged rats, and this dose level will be used to examine the therapeutic potential (efficacy) of LYT-100 during Phase 2.

[0691] Phase II studies

[0692] Subsequently, a Phase II study was conducted to evaluate the efficacy of LYT-100 in a rat BLM-induced pulmonary fibrosis model. The Phase II study design is provided in Table 32.

[0693] Table 32. BLM study design - Phase II

[0694]

[0695] For Groups 4, 5, 6, and 7, bleomycin and vehicle dosing (0.45 mg / kg, 1696 IU / mg bleomycin or saline on Days 1, 2, 3, 6, and 7) was performed as shown in Table 32. On Days 8-27, LYT-100 was administered once daily by oral gavage, and nintedanib was administered twice daily by oral gavage.

[0696] Observations

[0697] Animals were observed for various clinical signs and symptoms after administration of bleomycin, saline and LYT-100. The incidence of abnormal sounds in all animals administered bleomycin or saline on days 1, 2, 3, 6 and 7 was 100%, which was alleviated on the next study day, confirming administration to the lungs. From day 2, respiratory signs were observed in all animals administered bleomycin (Groups 5 to 7), with an incidence of 100% of increased respiratory rate from day 4 and until the end of the study on day 28. No increase in respiratory rate was observed in Group 4 receiving saline. Respiratory signs are an indication of acute inflammation secondary to bleomycin attack.

[0698] result

[0699] Body and lung weights were assessed during the study to determine the effects of bleomycin and LYT-100 in the model. In Groups 5, 6, and 7 receiving bleomycin, weight gain between Days 1 and 9 was prevented ( Fig.33A ). Continue to refer to Fig.33A , from the 10th day and until the end of the efficacy period on the 28th day, the weight gain in the 5th group (bleomycin / vehicle) and the 6th group (bleomycin / LYT-100) was restored, and its rate was similar to the 4th group receiving saline / vehicle. The weight gain in the 7th group (bleomycin / nintedanib) showed a moderate improvement after the 8th day, and the rate of weight gain was still slower than that in other groups. In the 5th, 6th and 7th groups receiving bleomycin, the weight gain (expressed as body weight % compared with the 1st day body weight) between the 1st day and the 9th day was prevented ( Fig.33B ). Continue to refer to Fig.33B From day 10 and until the end of the efficacy period at day 28, the % body weight gain in Group 5 (bleomycin / vehicle) and Group 6 (bleomycin / LYT-100) recovered and its rate was similar to that of Group 4 receiving saline / vehicle. The % body weight gain in Group 7 (bleomycin / nintedanib) showed a modest improvement after day 8, and the rate of body weight gain was still slower than that of the other groups.

[0700] Mean lung weights were increased in bleomycin-treated rats (Group 4, saline vs. Group 5, bleomycin; Fig.34A and Fig.34B ). Continue to refer to Fig.34A and Fig.34B , LYT-100 treatment did not affect the average lung weight of rats treated with bleomycin (Group 5, bleomycin / vehicle vs. Group 6, bleomycin / LYT-100). Nintedanib treated rats had reduced lung weight (Group 7 vs. Group 5), similar to unchallenged rats (Group 7 vs. Group 4). Lung weight ratios (expressed as % body weight in rats treated with bleomycin; Fig.35A and Fig.35B ) increased (Group 4, saline vs. Group 5, bleomycin). LYT-100 treatment did not affect the lung weight ratio of bleomycin-treated rats (Group 5, bleomycin / vehicle vs. Group 6, bleomycin / LYT-100). There was a trend toward a lower lung weight ratio in nintedanib-treated rats (Group 5 vs. Group 7), however, this lung weight ratio was still higher compared to unchallenged rats (Group 7 vs. Group 4).

[0701] Lung hydroxyproline content was measured in all groups ( Fig.36A , Fig.36B , Fig.37 , Fig.38A , Fig.38B , Fig.39 ). refer to Fig.36A , Fig.36B , Fig.37 , Fig.38A , Fig.38B and Fig.39 , total left lung hydroxyproline (μg / left lung) in rats treated with bleomycin was higher (Group 4, saline relative to Group 5, bleomycin). LYT-100 treatment did not affect the total hydroxyproline levels of rats treated with bleomycin (Group 5, bleomycin / vehicle relative to Group 6, bleomycin / LYT-100). Lungs from animals treated with nintedanib had lower levels of total hydroxyproline (Group 7 relative to Group 5), but were higher than rats not attacked (Group 7 relative to Group 4). The hydroxyproline content (μg / mg wet lung) in rats treated with bleomycin was higher (Group 4, saline relative to Group 5, bleomycin). LYT-100 treatment reduced the hydroxyproline content of rats treated with bleomycin (Group 5, bleomycin / vehicle relative to Group 6, bleomycin / LYT-100). Nintedanib treatment also reduced hydroxyproline content (Group 7 relative to Group 5).

[0702] Histopathological studies were performed to evaluate the extent of fibrosis in the lungs ( FIG. 40A to FIG. 40D and Fig.41). The average and median fibrosis scores in rats treated with bleomycin increased (Group 4, saline versus Group 5, bleomycin). LYT-100 or nintedanib treatment did not affect fibrosis scores (Group 5, bleomycin / vehicle versus Group 6, bleomycin / LYT-100 or Group 7, bleomycin / nintedanib). LYT-100 and nintedanib treatment reduced median fibrosis scores (Groups 6 and 7 compared to Group 5). Most of the fibrosis scores in Group 5 (bleomycin / vehicle) were distributed around scores 2 (39% of lung sections) and 3 (32% of lung sections). In LYT-100 and nintedanib treatments (Groups 6 and 7, respectively), the distribution of lung section fibrosis scores shifted to scores 1 (33% and 37%, respectively) and 2 (36% and 33%, respectively).

[0703] In general, 2 phases were performed according to the protocol, and there was no deviation from the integrity that was considered to affect the results of this phase. Reflecting phase 1, LYT-100 administered with 400mg / kg QD from the 8th day until (including) the 27th day was well tolerated by all animals, and any side effects observed disappeared within about 5 hours after being noticed, and did not reappear before the subsequent administration situation. The nintedanib administered with 60mg / kg twice a day (BID) was used as a reference. In contrast to nintedanib, LYT-100 does not negatively affect body weight development. LYT-100 reduces lung hydroxyproline content, thereby indicating that the presence of connective tissue in the lung is reduced. Consistent with the latter, compared with the vehicle control, the lungs of the rats treated with LYT-100 also have a reduced median fibrosis score.

[0704] Example 12: Exploration of the efficacy of LYT-100 in the treatment of myocardial fibrosis and heart failure

[0705] Patients with heart failure (HF) and evidence of myocardial fibrosis will be randomized to receive LYT-100 or placebo for a period of time.

[0706] Inclusion criteria may include one or more of the following: HF with preserved ejection fraction (HFpEF), HF with reduced ejection fraction, HF with mid-range ejection fraction, elevated natriuretic peptide levels, increased left ventricular end-diastolic diameter, contractile dyssynchrony, and elevated filling pressures. The extent of myocardial fibrosis may be measured using one or more of cardiovascular magnetic resonance imaging, myocardial extracellular volume, and load-independent intrinsic left ventricular myocardial stiffness.

[0707] Evaluation endpoints may include one or more of the following: reduction in myocardial extracellular volume (ECV); increase in 6-minute walk test (6MWT); improved KCCQ score (0-100); improved KCCQ clinical summary score (0-100); improved KCCQ total symptom score (0-100); improved left ventricular EDVi, ml m-2 ; Improved left ventricular ESVi, ml m -2 ; Improved left ventricular EF, %; Improved left ventricular mass index, gm -2 ; Improved native T1, ms; Improved absolute myocardial ECM volume, ml; Improved absolute myocardial cell volume, ml; Improved E / A ratio; Improved lateral e′, cm s -1 ; Septum e′, cm s -1 ; Improved average E / e′, cm s -1 ; Improved GLS, %; Improved PCr:ATP ratio (BCPSC); Improved right ventricular EDVi, ml m -2 ; Improved right ventricular EF (%); Improved right ventricular PAP, mm Hg; Improved left atrial volume, ml; Improved left atrial volume index, ml m -2 ; Improved LA strain (reservoir), %; Improved LA strain (boost), %; Improved LA strain (catheter), %.

Claims

1. A method of treating a fibrosis-mediated lung disease or condition, the method comprising administering to a subject in need thereof a total daily dose of about 825 mg to about 2475 mg of a deuterium-enriched pirfenidone having the structure: wherein the fibrosis-mediated pulmonary disease or disorder in the subject is treated.

2. The method of claim 1, wherein the total daily dose is 1650 mg.

3. The method of claim 1, wherein the total daily dose is 2475 mg.

4. The method of any one of claims 1 to 3, wherein the total daily dose is administered in three equal doses.

5. The method of claim 1, wherein the total daily dose is administered in three equal doses, each dose being 825 mg (825 mg TID).

6. The method of claim 1, wherein the total daily dose is administered in three equal doses, 550 mg each time (550 mg TID).

7. The method of any one of claims 1 to 6, wherein the LYT-100 is administered without regard for food.

8. The method of any one of claims 1 to 6, wherein the LYT-100 is administered without food.

9. The method of any one of claims 1 to 6, wherein the LYT-100 is administered with food.

10. The method of any one of claims 1 to 9, wherein the LYT-100 is administered without dose escalation.

11. The method of any one of claims 1 to 9, wherein administering comprises titrating upward to the total daily dose from an initial total daily dose that is lower than the total daily dose.

12. The method of claim 5, wherein administering comprises titrating up to the total daily dose from an initial total daily dose that is less than the total daily dose, and wherein titrating comprises administering the LYT-100 at a dose of 550 mg three times a day for three days followed by administering the LYT-100 at a dose of 825 mg three times a day.

13. The method of any one of claims 1 to 12, wherein the fibrosis-mediated lung disease or disorder is interstitial lung disease (ILD).

14. methods according to claim 13, wherein the ILD is the ILD that exposure is relevant, drug-induced ILD, autoimmune interstitial lung disease, the interstitial lung disease (uILD) that can not be classified, progressive fibrosing interstitial lung disease (pfILD), respiratory bronchiolitis-ILD ​​(RB-ILD), the ILD (CTD-ILD) that connective tissue disease is relevant, rheumatoid arthritis (RA-ILD), systemic sclerosis (SSc-ILD), mixed connective tissue disease-ILD, the ILD that scleroderma is relevant or the ILD relevant to chronic sarcoidosis.

15. The method of claim 13 or 14, wherein the ILD is progressive fibrosing ILD (PF-ILD).

16. The method of any one of claims 1 to 15, wherein a fibrosis or collagen-mediated disease or condition is alleviated.

17. The method of any one of claims 1 to 16, wherein the progression of the fibrosis or collagen-mediated disease or condition is delayed, slowed or arrested.